

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Sibship Size, Birth Order and Risk of Asthma and Allergy: Protocol for a Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045795
Article Type:	Protocol
Date Submitted by the Author:	12-Oct-2020
Complete List of Authors:	Lisik, Daniil; Sahlgrenska Academy, Medicine Özuygur Ermis, Saliha Selin; Dokuz Eylül University, Department of Pulmonology Goksör, Emma; Univ Gothenburg Wennergren, Göran; University of Gothenburg Sahlgrenska Academy, Krefting Research Centre; University of Gothenburg Sahlgrenska Academy, Dept of Paediatrics Nwaru, Bright; University of Gothenburg, Krefting Research Centre
Keywords:	Asthma < THORACIC MEDICINE, Allergy < THORACIC MEDICINE, Eczema < DERMATOLOGY, IMMUNOLOGY, Paediatric infectious disease & immunisation < PAEDIATRICS, Paediatric dermatology < PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Sibship Size, Birth Order and Risk of Asthma and Allergy: Protocol for a Systematic Review and Meta-Analysis

Daniil Lisik¹, Saliha Selin Özuygur Ermis², Emma Goksör³, Göran Wennergren³, Bright I Nwaru⁴

Author affiliations

¹ Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden

² Department of Pulmonology, Dokuz Eylul University, Izmir, Turkey

³ Department of Pediatrics, University of Gothenburg, Queen Silvia Children's Hospital, Gothenburg, Sweden.

⁴ Krefting Research Centre, Institute of Medicine, University of Gothenburg, Sweden

Correspondence to

Daniil Lisik

Institute of Medicine

Sahlgrenska Academy

University of Gothenburg, Sweden

guslisda@student.gu.se

Abstract

Introduction: The hygiene hypothesis suggests that reduced exposure to microbes might have contributed to the increase in prevalence and incidence of asthma and allergy observed during the second half of the last century. Following this proposal, several studies have investigated the role of sibship size and birth order in the development of asthma and allergic diseases, but the underlying evidence is conflicting. A systematic review will provide a clearer appreciation of the strength, magnitude, and quality of the underlying evidence.

Objective: To identify, critically appraise and synthesize previous primary studies investigating the association of sibship size and birth order with the risk of asthma and allergic diseases.

1
2
3 century, in particular in the developed world [1, 2]. More recent trends remain unclear, as
4 both increase [3] and leveling off [1, 4, 5] have been suggested. Around 300 million people
5 have asthma globally [1]. For allergic diseases, evidence indicates that there is still a global
6 increase in prevalence [5, 6]. Asthma and allergic diseases account for significant morbidity
7 for individuals, as well as a substantial socio-economic burden on the society [2]. Asthma
8 results in roughly 14 million missed school days each year in the United States alone, and the
9 morbidity is even higher for adults [7]. Allergic rhinitis is also associated with significant loss
10 in productivity [8]. Furthermore, the World Health Organization estimates that roughly
11 250,000 cases of death annually, worldwide, are due to asthma [7]. Identifying risk factors
12 for asthma and allergy is therefore of great interest, in order to reduce the burden associated
13 with these diseases.
14
15
16
17
18
19
20
21
22
23

24 Over the last five decades, numerous hypotheses have been proposed to explain the observed
25 increase in the prevalence of these diseases, a substantial part of the studies focusing on the
26 role of environmental factors. One of the main hypotheses is the hygiene hypothesis, which
27 was first proposed by Strachan in 1989, and suggests that reduced microbial exposure during
28 childhood increases the risk of developing asthma and allergy [9]. Connected to this
29 hypothesis is the proposed sibling effect, which suggests that the number of siblings and/or
30 the birth order of a child in a family may play a role in the development of asthma and
31 allergy, as a result of varying degrees of microbial exposure during childhood, depending on
32 the number of siblings in total and/or the number of older siblings [10].
33
34
35
36
37
38
39
40

41 While several studies have investigated the association of sibship (group of individuals
42 sharing the same pair of parents) size and birth order (the sequence in which members of a
43 sibship are born) with risk of asthma and allergic diseases, findings are conflicting [11]. So
44 far, there are no systematic reviews synthesizing evidence from previous studies on the topic.
45 A systematic synthesis of previous studies investigating the association of sibship size and
46 birth order with risk of asthma and allergy will provide a clearer appreciation of the strength,
47 magnitude, and quality of the underlying evidence.
48
49
50
51
52
53
54

55 **Aim**

56
57
58
59
60

To identify, critically appraise and synthesize previous primary studies investigating the association of sibship size and birth order with risk of asthma and allergic diseases.

Methods and analyses

This protocol is reported according to the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) [12], which provides guidelines for a standardized, transparent and reproducible reporting of systematic review protocols. Updates to the protocol will be documented, and deviations from the protocol will be described in the final review paper. The protocol for this systematic review has been prospectively registered with the international prospective register of systematic reviews (PROSPERO, <https://www.crd.york.ac.uk/PROSPERO>) and the registration number is being awaited.

Study eligibility criteria

Study types and publication status

We will include observational epidemiological studies, including prospective and retrospective cohort studies, case-control studies, and cross-sectional studies. Randomized controlled studies, quasi-randomized controlled studies, controlled before-after studies, and controlled clinical trials will not be considered, as interventional studies are not relevant for this research question. Animal studies, reviews, case studies, case series, expert opinions will also be excluded. Studies of any publication status will be eligible, and data used from them if available.

Participants

Offspring of any age, gender, ethnic background and medical background, where the study context is that the participants are part of defined sibships.

Exposures

Sibship size and birth order in the studied sibships.

Outcome measures

1
2
3 Self-reported or objectively measured/diagnosed asthma and allergic disease in the sibships.
4 For the purpose of encompassing all relevant literature on the topic, asthma and allergic
5 disease will be defined broadly. Asthma will be defined as any type of asthma, including
6 those based on symptom definition, such as wheezing, and those based on spirometry
7 findings of variable expiratory airflow limitation [13]. Allergic disease will encompass any of
8 the following: (a) allergic rhinitis/(rhino)conjunctivitis, food allergy, atopic eczema, urticaria,
9 angioedema, anaphylaxis [14]; (b) indicators of hypersensitivity (and indirectly of allergic
10 disease), which includes allergen-specific serum immunoglobulin E (IgE) test, skin prick test
11 (SPT), provocation/challenge test. Conditions with primarily a genetic etiology, such as
12 hereditary angioedema [15], will not be included in these definitions.
13
14
15
16
17
18
19
20
21

22 **Search methods**

23
24 The search queries were developed using the PEO model: population, exposure and outcome
25 (PEO). PEO is a specific implementation of PICO, used as a framework to produce effective
26 search queries from formulated research questions, especially befitting retrieval of
27 interventional and observational studies [16]. Since the population (P) will be defined
28 broadly, i.e., including both studies in children and adults, the actual search queries will be
29 composed of two blocks; exposure (E) and outcome (O). A scoping search was performed in
30 PubMed to identify previous studies on the topic and map relevant search terms. The search
31 terms identified were: Medical Subject Headings (MeSH), and their corresponding
32 alternatives in other databases; entry terms; free-text words and phrases. Subsequent scoping
33 searches were made in PubMed with boolean operator “NOT” between various MeSH and
34 free-text terms, alternately, in order to identify more synonyms and related search terms. The
35 developed search terms have been piloted and refined before they will be used to identify
36 relevant studies. The search queries have been modified for each database to be searched in
37 regards to, inter alia, support for controlled vocabulary and syntax. Peer Review of Electronic
38 Search Strategies (PRESS) has been used to identify potential weaknesses in the search
39 strategy. Details of the search strategy are presented in Appendix 1.
40
41
42
43
44
45
46
47
48
49
50
51

52
53 Studies will be retrieved from the following databases: AMED (via Ovid), CABI, CINAHL
54 (via EBSCO), Embase (via Ovid), Google Scholar, PsycINFO (via ProQuest), PubMed,
55 SciELO, Scopus, Web of Science, and WHO Global Index Medicus. In addition, unpublished
56
57
58
59
60

1
2
3 articles and gray literature will be retrieved through searches of OAIster, Open Access
4 Theses and Dissertations, Open Grey, and ProQuest Dissertations & Theses Global. Finally,
5 studies will also be included from reference lists of the studies included in the review, as well
6 as through contact with experts who have published in the field. All databases will be
7 searched for articles published from inception of respective database up until 31st December
8 2020; an updated search will be performed at the completion of the review to ensure
9 inclusion of studies published after the first search. There will be no language restrictions,
10 and articles will be translated into English where possible. Articles that could not be
11 translated will be reported in the final review paper. In Google Scholar, due to the fact that
12 the amount of results is sometimes overwhelming, results will be retrieved from the first 300
13 hits [17]. Furthermore, the search query for Google Scholar has been significantly simplified,
14 including only the most important terms in each block, due to an upper limit of 256
15 characters for search strings [18].

26 27 **Data management**

28 EndNote will be used for de-duplication, full-text retrieval, secondary screening, and for
29 general management of retrieved studies. For primary screening, the articles will be imported
30 to Rayyan QCRI.

34 35 **Screening/selection process**

36 The first stage of screening will be based on the title and/or abstract of the articles. Articles
37 that are clearly not relevant to the research question or clearly meet any of the exclusion
38 criteria will be excluded. Articles, where there is doubt about relevancy, will be included to
39 the next step. In the second stage of screening, the full text of the articles will be retrieved
40 and assessed for eligibility. The reason for each article not being included will be
41 documented and presented in a PRISMA flow diagram in the final review paper [19]. The
42 screening/selection will be independently performed by two reviewers. A third reviewer will
43 arbitrate any disagreement.

50 51 **Data extraction**

52 A data extraction form (Appendix 2) has been developed to extract data from included
53 studies in a standardized and reproducible fashion. The form will be piloted and revised
54
55
56
57
58
59
60

1
2
3 before being used in the review. If a study does not present needed data, authors of the study
4 will be contacted. Extracted data will be presented in table form. The extraction will be
5 independently conducted by two reviewers. A third reviewer will arbitrate any disagreement.
6
7
8
9

10 **Data items**

11 The following data items will be summarized from each study: author of publication; country
12 of origin of study; publication year; type of study design; sample size of study; source from
13 where study participants were recruited; definition and assessment of sibship and birth order;
14 duration of follow-up; confounding factors adjusted included in studies; study outcomes and
15 their assessment; analysis methods; and main results.
16
17
18
19
20
21

22 **Quality assessment**

23 Quality and risk of bias in the individual, included studies will be assessed using the
24 Effective Public Health Practice Project Quality Assessment Tool (EPHPP) [20]. The EPHPP
25 contains six domains of assessment for each study, including study design, selection bias,
26 confounding, blinding, study collection, withdrawals and dropouts. Based on the grading of
27 each of the six domains, a global quality grading will be derived for each study. Detailed
28 results will be presented in a separate table in the final review paper. Appraisal of quality and
29 risk of bias will be independently performed by two reviewers. A third reviewer will arbitrate
30 any disagreement.
31
32
33
34
35
36
37
38
39

40 **Data synthesis**

41 Descriptive tables will be generated to present the key characteristics of the included studies.
42 The produced evidence will be synthesized narratively. In addition, studies that present
43 comparable numerical data will be synthesized quantitatively with meta-analyses in RevMan
44 5, to produce pooled effect size estimates. Random-effects model will be applied in the meta-
45 analyses, because the included studies, solely based on published literature, are anticipated to
46 not be similar in every aspect and thus do not estimate the same effect. This model is more
47 conservative and provides a realistic scenario in the context of studies gathered solely from
48 published literature [21]. Separate meta-analyses will be undertaken for each of the factors
49 investigate (sibship size and birth order) in relation to each asthma and allergy outcome. The
50 results of the meta-analyses will be presented in forest plots.
51
52
53
54
55
56
57
58
59
60

Risk ratio (RR) will be used as the outcome measure in the meta-analyses, because of its intuitive interpretative feature [22]. Data from studies presenting effect measures as odds ratio (OR), incidence rate ratio (IRR), or hazard ratio (HR) will be converted to estimates of RR before combining with other studies, using the following formulas:

(a) $RR \approx IRR$;

(b) $RR \approx HR$ or OR (if outcome is $< 15\%$ by the end of follow-up);

(c) $RR \approx \sqrt{OR}$ or $\frac{1 - 0.5^{\sqrt{HR}}}{1 - 0.5^{\frac{1}{HR}}}$ (if outcome is $\geq 15\%$ by the end of follow-up) [23]

Calculation of I^2 will quantify heterogeneity between the included studies [24]. Consideration will be taken, regarding that this statistic can be biased in meta-analyses with few studies [25]. Subgroup analysis will be performed to explore potential reasons for heterogeneity between studies with the following subgroup variables: (a) study design; (b) quality appraisal of studies; (c) classification of the study country into “high-income”, “upper-middle-income”, “lower-middle-income”, and “low-income” economy, as defined by the World Bank [26]; (d) time during which the study was conducted, grouped into <1990 , $1990-1999$, $2000-2009$, and $2010-2020$. Subgroup analysis will be performed if there will be at least 4 (arbitrarily chosen cutoff [27]) studies in at least 2 subgroups. In addition, if more than 10 included studies present comparable numerical data [28], meta-regression will be performed to explore the impact of explanatory variables (covariates) on the observed heterogeneity in estimates across studies.

To investigate whether the conclusions of the review are independent of arbitrary decisions, sensitivity-analysis will be performed by only including studies which (a) reach either “strong” or “moderate” global rating of quality in accordance to EPHP; (b) have objectively verified diagnosis of asthma or allergic disease as outcome, with either ICD codes or verified medical examination as the basis for diagnosis. The sensitivity analysis will be reported in a summary table.

Publication bias

Publication bias will be assessed with Funnel plot, as well as Begg’s rank test and Egger’s regression test [29, 30]. In case of (significant) publication bias, the trim-and-fill method will be implemented to analyze its influence on the review results [31].

Ethics

Ethical approval will not be required due to the study being a systematic review of already published primary studies available in the public domain. Furthermore, patient consent will not be needed since data will be (or stay) aggregated [32, 33].

Patient and public involvement

No patients or participants were involved in the development of this protocol or the design of this study.

Discussion

The conclusions that will potentially be drawn from this systematic review, will be limited by the quality of the included studies. For this research question, the fact that all included studies will be observational limits the establishment of causality between sibship size, birth order, and risk of asthma and allergic diseases [34].

A strength of this study is the comprehensiveness of the search strategy, including 15 of the leading databases of formally published literature, as well as gray literature. There will be no restrictions in terms of language or geographical location. All these enable comprehensive identification of relevant studies for this research question. Furthermore, this systematic review will encompass a comprehensive spectrum of the most common asthma and allergic outcomes in relation to sibship size and birth order, thereby contributing to a broad overview of the existing evidence on the topic.

Asthma and allergic diseases pose a significant burden on both individuals and society. Whilst the role of sibship size and birth order in the development of these diseases have been investigated in several studies, albeit with conflicting evidence, a systematic review of existing studies is essential in providing a clearer appreciation of the underlying evidence. This protocol presents the methodology to perform a comprehensive systematic review and meta-analysis of existing literature on the topic.

Contributions

1
2
3 BIN conceived the study idea and research question. DL wrote the protocol, with review and general
4 suggestions for improvement from SSÖE, EG, GW, and BIN. Sectional authors approved the last version being
5 submitted.
6
7

8 **Funding**

9 There was no specific funding for this paper.
10
11
12

13 **Competing interests**

14 None declared.
15
16
17

18 **References**

- 19 1. Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. *Front Pediatr*. 2019;7:246.
- 20 2. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma Res Pract*. 2017;3:1.
- 21 3. Lundbäck B, Backman H, Lötvall J, Rönmark E. Is asthma prevalence still increasing? *Expert Rev Respir Med*.
22 2016;10(1):39-51.
- 23 4. Martinez FD. Trends in asthma prevalence, admission rates, and asthma deaths. *Respir Care*. 2008;53(5):561-565;
24 discussion 565-567.
- 25 5. Hicke-Roberts A, Åberg N, Wennergren G, Hesselmar B. Allergic rhinoconjunctivitis continued to increase in Swedish
26 children up to 2007, but asthma and eczema levelled off from 1991. *Acta Paediatr*. 2017;106(1):75-80.
- 27 6. Doll RJ, Joseph NI, McGarry D, Jhaveri D, Sher T, Hostoffer R. *Epidemiology of Allergic Diseases. Allergy and*
28 *Asthma: The Basics to Best Practices*. Cham: Springer International Publishing; 2019. p. 31-51.
- 29 7. Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. *World Allergy Organ J*.
30 2014;7(1):12.
- 31 8. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma
32 (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy*. 2008;63
33 Suppl 86:8-160.
- 34 9. Strachan DP. Hay fever, hygiene, and household size. *BMJ (Clinical research ed)*. 1989;299(6710):1259-1260.
- 35 10. Bloomfield SF, Rook GA, Scott EA, Shanahan F, Stanwell-Smith R, Turner P. Time to abandon the hygiene hypothesis:
36 new perspectives on allergic disease, the human microbiome, infectious disease prevention and the role of targeted hygiene.
37 *Perspect Public Health*. 2016;136(4):213-224.
- 38 11. Goldberg S, Israeli E, Schwartz S, Shochat T, Izbicki G, Toker-Maimon O, et al. Asthma prevalence, family size, and
39 birth order. *Chest*. 2007;131(6):1747-1752.
- 40 12. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic
41 review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*. 2015;4(1):1.
- 42 13. Zeller TA. Respiratory Conditions Update: Asthma. *FP Essent*. 2016;448:11-19.
- 43 14. Pinart M, Albang R, Maier D, Duran-Tauleria E, Mena G, Gimeno-Santos E, et al. Systematic Review on the Definition
44 of Allergic Diseases in Children: The MeDALL Study. *International Archives of Allergy and Immunology*.
45 2015;168(2):110-121.
- 46 15. Banerji A. Hereditary angioedema: classification, pathogenesis, and diagnosis. *Allergy Asthma Proc*. 2011;32(6):403-
47 407.
- 48 16. Khan KS, Kunz R, Kleijnen J, Antes G. Five steps to conducting a systematic review. *J R Soc Med*. 2003;96(3):118-121.
49
50
51
52
53
54
55
56
57
58
59
60

17. Haddaway NR, Collins AM, Coughlin D, Kirk S. The Role of Google Scholar in Evidence Reviews and Its Applicability to Grey Literature Searching. *PLOS ONE*. 2015;10(9):e0138237.
18. Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews or meta-analyses? Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. *Research Synthesis Methods*. 2020;11(2):181-217.
19. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *Bmj*. 2009;339:b2700.
20. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. *J Eval Clin Pract*. 2012;18(1):12-18.
21. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. *Res Synth Methods*. 2010;1(2):97-111.
22. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? *Bmj*. 1998;316(7136):989-991.
23. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. *Ann Intern Med*. 2017;167(4):268-274.
24. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Bmj*. 2003;327(7414):557-560.
25. von Hippel PT. The heterogeneity statistic I^2 can be biased in small meta-analyses. *BMC Med Res Methodol*. 2015;15:35.
26. World Bank. World Bank country and lending groups. Washington (DC): World Bank; 2020 [cited 2020 Sept 6]. Available from: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519>.
27. Fu R, Gartlehner G, Grant M, Shamliyan T, Sedrakyan A, Wilt TJ, et al. AHRQ Methods for Effective Health Care Conducting Quantitative Synthesis When Comparing Medical Interventions: AHRQ and the Effective Health Care Program. *Methods Guide for Effectiveness and Comparative Effectiveness Reviews*. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008.
28. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J. Meta-regression detected associations between heterogeneous treatment effects and study-level, but not patient-level, factors. *Journal of Clinical Epidemiology*. 2004;57(7):683-697.
29. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj*. 1997;315(7109):629-634.
30. Lin L, Chu H. Quantifying publication bias in meta-analysis. *Biometrics*. 2018;74(3):785-794.
31. Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large database of meta-analyses. *Medicine (Baltimore)*. 2019;98(23):e15987.
32. Wormald R, Evans J. What Makes Systematic Reviews Systematic and Why are They the Highest Level of Evidence? *Ophthalmic Epidemiology*. 2018;25(1):27-30.
33. Suri H. Ethical Considerations of Conducting Systematic Reviews in Educational Research. In: Zawacki-Richter O, Kerres M, Bedenlier S, Bond M, Buntins K, editors. *Systematic Reviews in Educational Research: Methodology, Perspectives and Application*. Wiesbaden: Springer Fachmedien Wiesbaden; 2020. p. 41-54.
34. Petrisor B, Bhandari M. The hierarchy of evidence: Levels and grades of recommendation. *Indian J Orthop*. 2007;41(1):11-15.

Appendix to
Sibship Size, Birth Order and Risk of Asthma and Allergy: Protocol for a Systematic
Review and Meta-Analysis

Daniil Lisik, Saliha Selin Özüygür Ermis, Emma Goksör, Göran Wennergren, Bright I Nwaru

Appendix 1: Search Strategies

Colorization

Red: controlled vocabulary/thesaurus

Blue: free-text

Green: referral to search query component (table row; #)

AMED

#	Search term(s)
1	(birth order* or birth rank* or multiple birth* or parity).mp.
2	exp Family Characteristics/ or (family characteristic* or family size* or family structure* or family demograph* or family composition or household size* or household demograph* or household composition).mp.
3	exp Sibling Relations/ or (sibling* or sister* or brother* or sibship size* or sibship*).mp.
4	or/1-3
5	exp Asthma/ or (bronchial asthma* or exercise-induced asthma* or exercise-induced bronchospasm* or asthma* or respiratory hypersensitivit* or airway hyper responsiveness or airway hyper-responsiveness or respiratory hyper responsiveness or respiratory hyper-responsiveness or wheez*).mp.
6	exp Hypersensitivity/ or exp Hypersensitivity Immediate/ or exp Hypersensitivity Delayed/ or (immediate hypersensitivit* or delayed hypersensitivit* or IgE-mediated hypersensitivit* or type I hypersensitivit* or type IV hypersensitivit* or atopic sensitization or atop* or allergic sensitization or allerg*).mp.
7	exp Dermatitis/ or exp Anaphylaxis/ or (atopic dermatitis or dermatitis or neurodermatiti* or besniers prurigo or besnier prurigo or atopic eczema or eczema or urticari* or anaphyla* or quinckes edema or quincke edema or angioneurotic edema or angioedema or hives).mp.
8	exp Food Hypersensitivity/ or (food hypersensitivit* or food allerg* or egg hypersensitivit* or egg allerg* or milk hypersensitivit* or milk allerg* or shellfish hypersensitivit* or shellfish allerg* or wheat hypersensitivit* or wheat allerg* or nut hypersensitivit* or nut allerg* or peanut hypersensitivit* or peanut allerg* or groundnut hypersensitivit* or groundnut allerg*).mp.

9	exp Rhinitis/ or exp Conjunctivitis/ or (allergic rhinoconjunctiviti* or rhinoconjunctiviti* or allergic rhiniti* or seasonal allergic rhiniti* or perennial allergic rhiniti* or rhiniti* or allergic conjunctiviti* or vernal keratoconjunctiviti* or vernal conjunctiviti* or giant papillary conjunctiviti* or hay fever or hayfever or pollinosis or nasal catarrh*).mp.
10	or/5-9
11	4 and 10
<p>Full query</p> <p>((birth order* or birth rank* or multiple birth* or parity).mp. or exp Family Characteristics/ or (family characteristic* or family size* or family structure* or family demograph* or family composition or household size* or household demograph* or household composition).mp. or exp Sibling Relations/ or (sibling* or sister* or brother* or sibship size* or sibship*).mp.) and (exp Asthma/ or (bronchial asthma* or exercise-induced asthma* or exercise-induced bronchospasm* or asthma* or respiratory hypersensitiv* or airway hyper responsiveness or airway hyper-responsiveness or respiratory hyper responsiveness or respiratory hyper-responsiveness or wheez*).mp. or exp Hypersensitivity/ or exp Hypersensitivity Immediate/ or exp Hypersensitivity Delayed/ or (immediate hypersensitiv* or delayed hypersensitiv* or IgE-mediated hypersensitiv* or type I hypersensitiv* or type IV hypersensitiv* or atopic sensitization or atop* or allergic sensitization or allerg*).mp. or exp Dermatitis/ or exp Anaphylaxis/ or (atopic dermatitis or dermatitis or neurodermatiti* or besniers prurigo or besnier prurigo or atopic eczema or eczema or urticari* or anaphyla* or quinckes edema or quincke edema or angioneurotic edema or angioedema or hives).mp. or exp Food Hypersensitivity/ or (food hypersensitiv* or food allerg* or egg hypersensitiv* or egg allerg* or milk hypersensitiv* or milk allerg* or shellfish hypersensitiv* or shellfish allerg* or wheat hypersensitiv* or wheat allerg* or nut hypersensitiv* or nut allerg* or peanut hypersensitiv* or peanut allerg* or groundnut hypersensitiv* or groundnut allerg*).mp. or exp Rhinitis/ or exp Conjunctivitis/ or (allergic rhinoconjunctiviti* or rhinoconjunctiviti* or allergic rhiniti* or seasonal allergic rhiniti* or perennial allergic rhiniti* or rhiniti* or allergic conjunctiviti* or vernal keratoconjunctiviti* or vernal conjunctiviti* or giant papillary conjunctiviti* or hay fever or hayfever or pollinosis or nasal catarrh*).mp.)</p>	

exp = include all narrower subject headings; mp= abstract, heading words, title

CABI; OAster; Open Access Theses and Dissertations; Open Grey; ProQuest
Dissertations & Theses Global; SciELO; WHO Global Index Medicus

#	Search term(s)
1	"birth order" OR "multiple births" OR "birth rank" OR "parity"
2	"family characteristics" OR "family size" OR "family structure" OR "family demography" OR "family composition" OR "household size" OR "household demography" OR "household composition"
3	"siblings" OR "sibling relations" OR "sister" OR "brother" OR "sibship"
4	"exercise-induced bronchospasm" OR "asthma" OR "airway hyper-responsiveness" OR "respiratory hyper-responsiveness" OR "wheeze" OR "wheezing"
5	"hypersensitivity" OR "atopic sensitization" OR "atopy" OR "allergic sensitization" OR "allergic disease" OR "allergic condition" OR "allergy" OR "allergies"

6	"dermatitis" OR "eczema" OR "neurodermatitis" OR "besnier's prurigo" OR "urticaria" OR "anaphylaxis" OR "anaphylactic shock" OR "quincke's edema" OR "angionuerotic edema" OR "angioedema" OR "hives"
8	"rhinoconjunctivitis" OR "rhinitis" OR "allergic conjunctivitis" OR "vernal keratoconjunctivitis" OR "vernal conjunctivitis" OR "giant papillary conjunctivitis" OR "hay fever" OR "pollinosis" OR "pollenosis" OR "nasal catarrh"
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
Full query ("birth order" OR "multiple births" OR "birth rank" OR "parity" OR "family characteristics" OR "family size" OR "family structure" OR "family demography" OR "family composition" OR "household size" OR "household demography" OR "household composition" OR "siblings" OR "sibling relations" OR "sister" OR "brother" OR "sibship") AND ("exercise-induced bronchospasm" OR "asthma" OR "airway hyper-responsiveness" OR "respiratory hyper-responsiveness" OR "wheeze" OR "wheezing" OR "hypersensitivity" OR "atopic sensitization" OR "atopy" OR "allergic sensitization" OR "allergic disease" OR "allergic condition" OR "allergy" OR "allergies" OR "dermatitis" OR "eczema" OR "neurodermatitis" OR "besnier's prurigo" OR "urticaria" OR "anaphylaxis" OR "anaphylactic shock" OR "quincke's edema" OR "angionuerotic edema" OR "angioedema" OR "hives" OR "rhinoconjunctivitis" OR "rhinitis" OR "allergic conjunctivitis" OR "vernal keratoconjunctivitis" OR "vernal conjunctivitis" OR "giant papillary conjunctivitis" OR "hay fever" OR "pollinosis" OR "pollenosis" OR "nasal catarrh")	

CINAHL

#	Search term(s)
1	(MH 'Birth Order+') OR (MH 'Parity+') OR 'birth order*' OR 'birth rank*' OR 'multiple birth*' OR 'parity'
2	(MH 'Family Characteristics+') OR (MH 'Family Health+') OR 'family charactersitic*' OR 'family size*' OR 'family structure*' OR 'family demograph*' OR 'family composition' OR 'household size*' OR 'household demograph*' OR 'household composition'
3	(MH 'Siblings+') OR (MH 'Sibling Relations+') OR 'sibling*' OR 'sister*' OR 'brother*' OR 'sibship size*' OR 'sibship*'
4	(MH 'Asthma+') OR (MH 'Respiratory Hypersensitivity+') OR 'bronchial asthma*' OR 'exercise-induced asthma' OR 'asthma*' OR 'exercise-induced bronchospasm' OR 'respiratory hypersensitivit*' OR 'airway hyper responsiveness' OR 'airway hyper-responsiveness' OR 'respiratory hyper responsiveness' OR 'respiratory hyper-responsiveness' OR 'wheeze*'
5	(MH 'Hypersensitivity+') OR (MH 'Hypersensitivity, Immediate+') OR (MH 'Hypersensitivity, Delayed+') OR (MH 'Allergy and Immunology+') OR 'immedate hypersensitivit*' OR 'delayed hypersensitivit*' OR 'IgE-mediated hypersensitivit*' OR 'type I hypersensitivit*' OR 'type IV hypersensitivit*' OR 'hypersensitivit*' OR 'atopic sensitization' OR 'atop*' OR 'allergic sensitization' OR 'allergic disease*' OR 'allerg*'

6	(MH 'Dermatitis, Atopic+') OR (MH 'Eczema+') OR (MH 'Angioedema+') OR (MH 'Anaphylaxis+') OR (MH 'Urticaria+') OR 'atopic dermatitis' OR 'dermatitis' OR 'atopic eczema' OR 'eczema' OR 'nerudoarmatiti*' OR "besnier's prurigo" OR 'besniers prurigo' OR 'besnier prurigo' OR 'urticari*' OR 'hives' OR 'anaphyla*' OR "quincke's edema" OR 'quinckes edema' OR 'quincke edema' OR 'angioneurotic edema' OR 'angioedema'
7	(MH 'Food Hypersensitivity+') OR 'food hypersensitivit*' OR 'food allerg*' OR 'egg hypersensitivit*' OR 'egg allerg*' OR 'milk hypersensitivit*' OR 'milk allerg*' OR 'shellfish hypersensitivit*' OR 'shellfish allerg*' OR 'wheat hypersensitivit*' OR 'wheat allerg*' OR 'nut hypersensitivit*' OR 'nut allerg*' OR 'peanut hypersensitivit*' OR 'peanut allerg*' OR 'groundnut hypersensitivit*' OR 'groundnut allerg*'
8	(MH 'Rhinitis, Allergic+') OR (MH 'Rhinitis, Allergic, Seasonal+') OR (MH 'Rhinitis, Allergic, Perennial+') OR (MH 'Rhinitis+') OR (MH 'Conjunctivitis, Allergic+') OR (MH 'Conjunctivitis+') OR 'allergic rhinoconjunctiviti*' OR 'rhinoconjunctiviti*' OR 'allergic rhiniti*' OR 'seasonal allergic rhiniti*' OR 'perennial allergic rhiniti*' OR 'rhiniti*' OR 'allergic conjunctiviti*' OR 'vernal keratoconjunctiviti*' OR 'vernal conjunctiviti*' OR 'giant papillary conjunctiviti*' OR 'hay fever' OR 'hayfever' OR 'pollinosis' OR 'pollenosis' OR 'nasal catarrh'
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
<p>Full query</p> <p>((MH "Birth Order+") OR (MH "Parity+") OR "birth order*" OR "birth rank*" OR "multiple birth*" OR "parity" OR (MH "Family Characteristics+") OR (MH "Family Health+") OR "family charactersitic*" OR "family size*" OR "family structure*" OR "family demograph*" OR "family composition" OR "household size*" OR "household demograph*" OR "household composition" OR (MH "Siblings+") OR (MH "Sibling Relations+") OR "sibling*" OR "sister*" OR "brother*" OR "sibship size*" OR "sibship*") AND ((MH "Asthma+") OR (MH "Respiratory Hypersensitivity+") OR "bronchial asthma*" OR "exercise-induced asthma" OR "asthma*" OR "exercise-induced bronchospasm" OR "respiratory hypersensitivit*" OR "airway hyper responsiveness" OR "airway hyper-responsiveness" OR "respiratory hyper responsiveness" OR "respiratory hyper-responsiveness" OR "wheez*" OR (MH "Hypersensitivity+") OR (MH "Hypersensitivity, Immediate+") OR (MH "Hypersensitivity, Delayed+") OR (MH "Allergy and Immunology+") OR "immedate hypersensitivit*" OR "delayed hypersensitivit*" OR "IgE-mediated hypersensitivit*" OR "type I hypersensitivit*" OR "type IV hypersensitivit*" OR "hypersensitivit*" OR "atopic sensitization" OR "atop*" OR "allergic sensitization" OR "allergic disease*" OR "allerg*" OR (MH "Dermatitis, Atopic+") OR (MH "Eczema+") OR (MH 'Angioedema+') OR (MH 'Anaphylaxis+') OR (MH "Urticaria+") OR "atopic dermatitis" OR "dermatitis" OR "atopic eczema" OR "eczema" OR "nerudoarmatiti*" OR "besnier's prurigo" OR "besniers prurigo" OR "besnier prurigo" OR "urticari*" OR "hives" OR "anaphyla*" OR "quincke's edema" OR "quinckes edema" OR "quincke edema" OR "angioneurotic edema" OR "angioedema" OR (MH "Food Hypersensitivity+") OR "food hypersensitivit*" OR "food allerg*" OR "egg hypersensitivit*" OR "egg allerg*" OR "milk hypersensitivit*" OR "milk allerg*" OR "shellfish hypersensitivit*" OR "shellfish allerg*" OR "wheat hypersensitivit*" OR "wheat allerg*" OR "nut hypersensitivit*" OR "nut allerg*" OR "peanut hypersensitivit*" OR "peanut allerg*" OR "groundnut hypersensitivit*" OR "groundnut allerg*" OR (MH "Rhinitis, Allergic+") OR (MH "Rhinitis, Allergic, Seasonal+") OR (MH "Rhinitis, Allergic, Perennial+") OR (MH "Rhinitis+") OR (MH "Conjunctivitis, Allergic+") OR (MH "Conjunctivitis+") OR "allergic rhinoconjunctiviti*" OR "rhinoconjunctiviti*" OR</p>	

"allergic rhiniti*" OR "seasonal allergic rhiniti*" OR "perennial allergic rhiniti*" OR "rhiniti*" OR "allergic conjunctiviti*" OR "vernal keratoconjunctiviti*" OR "vernal conjunctiviti*" OR "giant papillary conjunctiviti*" OR "hay fever" OR "hayfever" OR "pollinosis" OR "pollenosis" OR "nasal catarrh"))

MH = subject heading

Embase

#	Search term(s)
1	sibship.mp.
2	birth order.mp. or exp birth order/
3	birth rank.mp.
4	multiple birth.mp.
5	parity.mp. or exp parity/
6	family characteristic.mp. or exp family size/
7	family structure.mp.
8	family demograph.mp.
9	family demograph*.mp.
10	family composition.mp.
11	household size.mp.
12	household demograph*.mp.
13	household composition.mp.
14	exp sibling relation/ or sibling.mp. or sibling/
15	exp sister/ or sister.mp.
16	siblings.mp.
17	sisters.mp.
18	brother.mp. or exp brother/
19	brothers.mp.
20	or/1-19
21	exp Asthma/ or (bronchial asthma* or exercise-induced asthma* or exercise-induced bronchospasm* or asthma* or respiratory hypersensitivit* or airway hyper responsiveness or airway hyper-responsiveness or respiratory hyper responsiveness or respiratory hyper-responsiveness or wheez*).mp.
22	exp Hypersensitivity/ or exp Hypersensitivity Immediate/ or exp Hypersensitivity Delayed/ or (immediate hypersensitivit* or delayed hypersensitivit* or IgE-mediated hypersensitivit* or type I hypersensitivit* or type IV hypersensitivit* or atopic sensitization or atop* or allergic sensitization or allerg*).mp.
23	exp Dermatitis/ or exp Anaphylaxis/ or (atopic dermatitis or dermatitis or neurodermatiti* or besnier prurigo or besniers prurigo or besnier prurigo or atopic eczema or eczema or urticari* or anaphyla* or quincke edema or quinckes edema or quincke edema or angioneurotic edema or angioedema or hives).mp.

24	exp Food Hypersensitivity/ or (food hypersensitivit* or food allerg* or egg hypersensitivit* or egg allerg* or milk hypersensitivit* or milk allerg* or shellfish hypersensitivit* or shellfish allerg* or wheat hypersensitivit* or wheat allerg* or nut hypersensitivit* or nut allerg* or peanut hypersensitivit* or peanut allerg* or groundnut hypersensitivit* or groundnut allerg*).mp.
25	exp Rhinitis/ or exp Conjunctivitis/ or (allergic rhinoconjunctiviti* or rhinoconjunctiviti* or allergi rhiniti* or seasonal allergic rhiniti* or perennial allergic rhiniti* or rhiniti* or allergic conjunctiviti* or vernal keratoconjunctiviti* or vernal conjunctiviti* or giant papillary conjunctiviti* or hay fever or hayfever or pollinosis or pollinosis or nasal catarrh*).mp.
26	or/21-25
27	20 and 26

Google Scholar

#	Search term(s)
1	"family size" OR "family structure" OR "household size"
2	"sibling" OR "sibship"
3	"asthma" OR "wheezing"
4	"atopy" OR "allergy"
5	"eczema" OR "urticaria" OR "angioedema" OR "anaphylaxis"
6	"rhinitis" OR "allergic conjunctivitis" OR "hay fever"
7	1 OR 2
8	3 OR 4 OR 5 OR 6
9	7 AND 8
Full query ("family size" OR "family structure" OR "household size" OR "sibling" OR "sibship") AND ("asthma" OR "wheezing" OR "atopy" OR "allergy" OR "anaphylaxis" OR "eczema" OR "urticaria" OR "angioedema" OR "rhinitis" OR "allergic conjunctivitis" OR "hay fever")	

PsycINFO

#	Search term(s)
1	SU.EXACT.EXPLODE("Birth Order") OR TI,AB("birth order*") OR TI,AB("multiple birth*") OR TI,AB("birth rank*") OR TI,AB("parity")
2	SU.EXACT.EXPLODE("Family Structure") OR SU.EXACT.EXPLODE("Family Size") OR TI,AB("family characteristic*") OR TI,AB("family size*") OR TI,AB("family structure*") OR TI,AB("family demograph*") OR TI,AB("family composition") OR TI,AB("household size*") OR TI,AB("household demograph*") OR TI,AB("household composition")
3	SU.EXACT.EXPLODE("Siblings") OR SU.EXACT.EXPLODE("Sibling Relations") OR TI,AB("sibling*") OR TI,AB("sister*") OR TI,AB("brother*") OR TI,AB("sibship size*") OR TI,AB("sibship size*") OR TI,AB("sibship*")

4	SU.EXACT.EXPLODE("Asthma") OR TI,AB("bronchial asthma*") OR TI,AB("exercise-induced asthma*") OR TI,AB("asthma*") OR TI,AB("exercise-induced bronchospasm*") OR TI,AB("respiratory hypersensitivit*") OR TI,AB("airway hyper responsiveness") OR TI,AB("airway hyper-responsiveness") OR TI,AB("respiratory hyper responsiveness") OR TI,AB("respiratory hyper-responsiveness") OR TI,AB("wheez*")
5	SU.EXACT.EXPLODE("Allergic Disorders") OR TI,AB("immediate hypersensitivit*") OR TI,AB("delayed hypersensitivit*") OR TI,AB("hypersensitivit*") OR TI,AB("IgE-mediated hypersensitivit*") OR TI,AB("type I hypersensitivit*") OR TI,AB("type IV hypersensitivit*") OR TI,AB("atopic sensitization") OR TI,AB("atop*") OR TI,AB("allergic sensitization") OR TI,AB("allergic disease*") OR TI,AB("allerg*")
6	SU.EXACT.EXPLODE("Allergic Skin Disorders") OR SU.EXACT.EXPLODE("Neurodermatitis") OR SU.EXACT.EXPLODE("Dermatitis") OR SU.EXACT.EXPLODE("Eczema") OR SU.EXACT.EXPLODE("Anaphylactic Shock") OR TI,AB("atopic dermatitis") OR TI,AB("dermatitis") OR TI,AB("atopic eczema") OR TI,AB("eczema") OR TI,AB("neurodermatiti*") OR TI,AB("besnier's prurigo") OR TI,AB("besniers prurigo") OR TI,AB("besnier prurigo") OR TI,AB("urticari*") OR TI,AB("hives") OR TI,AB("anaphyla*") OR TI,AB("quincke's edema") OR TI,AB("quinckes edema") OR TI,AB("quincke edema") OR TI,AB("angioneurotic edema") OR TI,AB("angioedema")
7	SU.EXACT.EXPLODE("Food Allergies") OR TI,AB("food hypersensitivit*") OR TI,AB("food allerg*") OR TI,AB("egg hypersensitivit*") OR TI,AB("egg allerg*") OR TI,AB("milk hypersensitivit*") OR TI,AB("milk allerg*") OR TI,AB("shellfish hypersensitivit*") OR TI,AB("shellfish allerg*") OR TI,AB("wheat hypersensitivit*") OR TI,AB("wheat allerg*") OR TI,AB("nut hypersensitivit*") OR TI,AB("nut allerg*") OR TI,AB("peanut hypersensitivit*") OR TI,AB("peanut allerg*") OR TI,AB("groundnut hypersensitivit*") OR TI,AB("groundnut allerg*")
8	TI,AB("allergic rhinoconjunctiviti*") OR TI,AB("rhinoconjunctiviti*") OR TI,AB("allergic rhiniti*") OR TI,AB("rhiniti*") OR TI,AB("seasonal allergic rhiniti*") OR TI,AB("perennial allergic rhiniti*") OR TI,AB("allergic conjunctiviti*") OR TI,AB("vernal keratoconjunctiviti*") OR TI,AB("vernal conjunctiviti*") OR TI,AB("giant papillary conjunctiviti*") OR TI,AB("hay fever") OR TI,AB("hayfever") OR TI,AB("pollinosis") OR TI,AB("pollenosis") OR TI,AB("nasal catarrh*")
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
<p>Full query</p> <p>(SU.EXACT.EXPLODE("Birth Order") OR TI,AB("birth order*") OR TI,AB("multiple birth*") OR TI,AB("birth rank*") OR TI,AB("parity") OR SU.EXACT.EXPLODE("Family Structure") OR SU.EXACT.EXPLODE("Family Size") OR TI,AB("family characteristic*") OR TI,AB("family size*") OR TI,AB("family structure*") OR TI,AB("family demograph*") OR TI,AB("family composition") OR TI,AB("household size*") OR TI,AB("household demograph*") OR TI,AB("household composition") OR SU.EXACT.EXPLODE("Siblings") OR SU.EXACT.EXPLODE("Sibling Relations") OR TI,AB("sibling*") OR TI,AB("sister*") OR TI,AB("brother*") OR</p>	

TI,AB("sibship size*") OR TI,AB("sibship size*") OR TI,AB("sibship*") AND (SU.EXACT.EXPLODE("Asthma") OR TI,AB("bronchial asthma*") OR TI,AB("exercise-induced asthma*") OR TI,AB("asthma*") OR TI,AB("exercise-induced bronchospasm*") OR TI,AB("respiratory hypersensitivit*") OR TI,AB("airway hyper responsiveness") OR TI,AB("airway hyper-responsiveness") OR TI,AB("respiratory hyper responsiveness") OR TI,AB("respiratory hyper-responsiveness") OR TI,AB("wheez*") OR SU.EXACT.EXPLODE("Allergic Disorders") OR TI,AB("immediate hypersensitivit*") OR TI,AB("delayed hypersensitivit*") OR TI,AB("hypersensitivit*") OR TI,AB("IgE-mediated hypersensitivit*") OR TI,AB("type I hypersensitivit*") OR TI,AB("type IV hypersensitivit") OR TI,AB("atopic sensitization") OR TI,AB("atop*") OR TI,AB("allergic sensitization") OR TI,AB("allergic disease*") OR TI,AB("allerg*") OR SU.EXACT.EXPLODE("Allergic Skin Disorders") OR SU.EXACT.EXPLODE("Neurodermatitis") OR SU.EXACT.EXPLODE("Dermatitis") OR SU.EXACT.EXPLODE("Eczema") OR SU.EXACT.EXPLODE("Anaphylactic Shock") OR TI,AB("atopic dermatitis") OR TI,AB("dermatitis") OR TI,AB("atopic eczema") OR TI,AB("eczema") OR TI,AB("neurodermatiti*") OR TI,AB("besnier's prurigo") OR TI,AB("besniers prurigo") OR TI,AB("besnier prurigo") OR TI,AB("urticari*") OR TI,AB("hives") OR TI,AB("anaphyla*") OR TI,AB("quincke's edema") OR TI,AB("quinckes edema") OR TI,AB("quincke edema") OR TI,AB("angioneurotic edema") OR TI,AB("angioedema") OR SU.EXACT.EXPLODE("Food Allergies") OR TI,AB("food hypersensitivit*") OR TI,AB("food allerg*") OR TI,AB("egg hypersensitivit*") OR TI,AB("egg allerg*") OR TI,AB("milk hypersensitivit*") OR TI,AB("milk allerg*") OR TI,AB("shellfish hypersensitivit*") OR TI,AB("shellfish allerg*") OR TI,AB("wheat hypersensitivit*") OR TI,AB("wheat allerg*") OR TI,AB("nut hypersensitivit*") OR TI,AB("nut allerg*") OR TI,AB("peanut hypersensitivit*") OR TI,AB("peanut allerg*") OR TI,AB("groundnut hypersensitivit*") OR TI,AB("groundnut allerg*") OR TI,AB("allergic rhinoconjunctiviti*") OR TI,AB("rhinoconjunctiviti*") OR TI,AB("allergic rhiniti*") OR TI,AB("rhiniti*") OR TI,AB("seasonal allergic rhiniti*") OR TI,AB("perennial allergic rhiniti*") OR TI,AB("allergic conjunctiviti*") OR TI,AB("vernal keratoconjunctiviti*") OR TI,AB("vernal conjunctiviti*") OR TI,AB("giant papillary conjunctiviti*") OR TI,AB("hay fever") OR TI,AB("hayfever") OR TI,AB("pollinosis") OR TI,AB("pollenosis") OR TI,AB("nasal catarrh*"))

SU = all subjects and indexing; TI,AB = title, abstract

PubMed

#	Search term(s)
1	Birth Order[mh] OR Parity[mh] OR birth order*[tiab] OR multiple birth*[tiab] OR birth rank*[tiab] OR parity[tiab]
2	Family Characteristics[mh] OR Family Health[mh] OR family characteristic*[tiab] OR family size*[tiab] OR family structure*[tiab] OR family demograph*[tiab] OR family composition[tiab] OR household size*[tiab] OR household demograph*[tiab] OR household composition[tiab]
3	Siblings[mh] OR Sibling Relations[mh] OR sibling*[tiab] OR sister*[tiab] OR brother*[tiab] OR sibship size*[tiab] OR sibship*[tiab]
4	Asthma[mh] OR Asthma, Exercise-Induced[mh] OR Respiratory Hypersensitivity[mh] OR bronchial asthma*[tiab] OR exercise-induced asthma*[tiab] OR exercise-induced bronchospasm*[tiab] OR asthma*[tiab] OR respiratory hypersensitivit*[tiab] OR airway hyper responsiveness[tiab] OR airway hyper-responsiveness[tiab] OR respiratory hyper responsiveness[tiab] OR respiratory hyper-responsiveness[tiab] OR wheez*[tiab]

5	Hypersensitivity[mh] OR Hypersensitivity, Immediate[mh] OR Hypersensitivity, Delayed[mh] OR Allergy and Immunology[mh] OR Allergens / Immunology[mh] OR immediate hypersensitivit*[tiab] OR delayed hypersensitivit*[tiab] OR hypersensitivit*[tiab] OR IgE-mediated hypersensitivit*[tiab] OR type I hypersensitivit*[tiab] OR type IV hypersensitivit*[tiab] OR atopic sensitization[tiab] OR atop*[tiab] OR allergic sensitization[tiab] OR allergic disease*[tiab] OR allerg*[tiab]
6	Dermatitis, Atopic[mh] OR Eczema[mh] OR Angioedema[mh] OR Anaphylaxis[mh] OR Urticaria[mh] OR atopic dermatitis[tiab] OR dermatitis[tiab] OR atopic eczema[tiab] OR eczema[tiab] OR neurodermatiti*[tiab] OR besnier's prurigo[tiab] OR besniers prurigo[tiab] OR besnier prurigo[tiab] OR urticari*[tiab] OR anaphyla*[tiab] OR quincke edema[tiab] OR quinckes edema[tiab] OR quincke's edema[tiab] OR angioneurotic edema[tiab] OR angioedema[tiab] OR hives[tiab]
7	Food Hypersensitivity[mh] OR food hypersensitivit*[tiab] OR food allerg*[tiab] OR egg allerg*[tiab] OR egg hypersensitivit*[tiab] OR milk allerg*[tiab] OR milk hypersensitivit*[tiab] OR shellfish allerg*[tiab] OR shellfish hypersensitivit*[tiab] OR wheat allerg*[tiab] OR wheat hypersensitivit*[tiab] OR nut allerg*[tiab] OR nut hypersensitivit*[tiab] OR peanut allerg*[tiab] OR peanut hypersensitivit*[tiab] OR groundnut hypersensitivit*[tiab]
8	Pollen / Immunology[mh] OR Rhinitis, Allergic[mh] OR Rhinitis, Allergic, Seasonal[mh] OR Rhinitis, Allergic, Perennial[mh] OR Rhinitis[mh] OR Conjunctivitis, Allergic[mh] OR Conjunctivitis / Immunology[mh] OR Conjunctivitis / Epidemiology[mh] OR Conjunctivitis / Etiology[mh] OR allergic rhinoconjunctiviti*[tiab] OR rhinoconjunctiviti*[tiab] OR allergic rhiniti*[tiab] OR rhiniti*[tiab] OR seasonal allergic rhiniti*[tiab] OR perennial allergic rhiniti*[tiab] OR allergic conjunctiviti*[tiab] OR vernal keratoconjunctiviti*[tiab] OR vernal conjunctiviti*[tiab] OR giant papillary conjunctiviti*[tiab] OR hay fever[tiab] OR hayfever[tiab] OR pollinosis[tiab] OR pollenosis[tiab] OR nasal catarrh*[tiab]
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
<p>Full query</p> <p>(Birth Order[mh] OR Parity[mh] OR birth order*[tiab] OR multiple birth*[tiab] OR birth rank*[tiab] OR parity[tiab] OR Family Characteristics[mh] OR Family Health[mh] OR family characteristic*[tiab] OR family size*[tiab] OR family structure*[tiab] OR family demograph*[tiab] OR family composition[tiab] OR household size*[tiab] OR household demograph*[tiab] OR household composition[tiab] OR Siblings[mh] OR Sibling Relations[mh] OR sibling*[tiab] OR sister*[tiab] OR brother*[tiab] OR sibship size*[tiab] OR sibship*[tiab]) AND (Asthma[mh] OR Asthma, Exercise-Induced[mh] OR Respiratory Hypersensitivity[mh] OR bronchial asthma*[tiab] OR exercise-induced asthma*[tiab] OR exercise-induced bronchospasm*[tiab] OR asthma*[tiab] OR respiratory hypersensitivit*[tiab] OR airway hyper responsiveness[tiab] OR airway hyper-responsiveness[tiab] OR respiratory hyper responsiveness[tiab] OR respiratory hyper-responsiveness[tiab] OR wheez*[tiab] OR Hypersensitivity[mh] OR Hypersensitivity, Immediate[mh] OR Hypersensitivity, Delayed[mh] OR Allergy and Immunology[mh] OR Allergens / Immunology[mh] OR immediate hypersensitivit*[tiab] OR delayed hypersensitivit*[tiab] OR hypersensitivit*[tiab] OR IgE-mediated hypersensitivit*[tiab] OR type I hypersensitivit*[tiab] OR type IV hypersensitivit*[tiab] OR atopic sensitization[tiab] OR atop*[tiab] OR allergic sensitization[tiab] OR allergic disease*[tiab] OR allerg*[tiab] OR Dermatitis, Atopic[mh] OR Eczema[mh] OR Angioedema[mh] OR Anaphylaxis[mh] OR Urticaria[mh] OR atopic dermatitis[tiab] OR dermatitis[tiab] OR atopic eczema[tiab] OR eczema[tiab] OR neurodermatiti*[tiab] OR besnier's prurigo[tiab] OR besniers prurigo[tiab] OR besnier prurigo[tiab] OR urticari*[tiab] OR anaphyla*[tiab] OR quincke edema[tiab] OR quinckes edema[tiab] OR quincke's edema[tiab] OR angioneurotic edema[tiab] OR angioedema[tiab] OR hives[tiab])</p>	

OR Food Hypersensitivity[mh] OR food hypersensitiv*[tiab] OR food allerg*[tiab] OR egg allerg*[tiab] OR egg hypersensitiv*[tiab] OR milk allerg*[tiab] OR milk hypersensitiv*[tiab] OR shellfish allerg*[tiab] OR shellfish hypersensitiv*[tiab] OR wheat allerg*[tiab] OR wheat hypersensitiv*[tiab] OR nut allerg*[tiab] OR nut hypersensitiv*[tiab] OR peanut allerg*[tiab] OR peanut hypersensitiv*[tiab] OR groundnut hypersensitiv*[tiab] OR Pollen / Immunology[mh] OR Rhinitis, Allergic[mh] OR Rhinitis, Allergic, Seasonal[mh] OR Rhinitis, Allergic, Perennial[mh] OR Rhinitis[mh] OR Conjunctivitis, Allergic[mh] OR Conjunctivitis / Immunology[mh] OR Conjunctivitis / Epidemiology[mh] OR Conjunctivitis / Etiology[mh] OR allergic rhinoconjunctiviti*[tiab] OR rhinoconjunctiviti*[tiab] OR allergic rhiniti*[tiab] OR rhiniti*[tiab] OR seasonal allergic rhiniti*[tiab] OR perennial allergic rhiniti*[tiab] OR allergic conjunctiviti*[tiab] OR vernal keratoconjunctivitis*[tiab] OR vernal conjunctiviti*[tiab] OR giant papillary conjunctiviti*[tiab] OR hay fever[tiab] OR hayfever[tiab] OR pollinosis[tiab] OR pollinosis[tiab] OR nasal catarrh*[tiab])

mh = MeSH; tiab = title, abstract

Scopus

#	Search term(s)
1	TITLE-ABS-KEY("birth order*") OR TITLE-ABS-KEY("multiple birth*") OR TITLE-ABS-KEY("birth rank*") OR TITLE-ABS-KEY("parity")
2	TITLE-ABS-KEY("family characteristic*") OR TITLE-ABS-KEY("family size*") OR TITLE-ABS-KEY("family structure*") OR TITLE-ABS-KEY("family demograph*") OR TITLE-ABS-KEY("family composition") OR TITLE-ABS-KEY("household size*") OR TITLE-ABS-KEY("household demograph*") OR TITLE-ABS-KEY("household composition*")
3	TITLE-ABS-KEY("sibling relation*") OR TITLE-ABS-KEY("sibling*") OR TITLE-ABS-KEY("brother*") OR TITLE-ABS-KEY("sister*") OR TITLE-ABS-KEY("sibship size*") OR TITLE-ABS-KEY("sibship*")
4	TITLE-ABS-KEY("bronchial asthma*") OR TITLE-ABS-KEY("exercise-induced asthma*") OR TITLE-ABS-KEY("asthma*") OR TITLE-ABS-KEY("exercise-induced bronchospasm*") OR TITLE-ABS-KEY("respiratory hypersensitiv*") OR TITLE-ABS-KEY("airway hyper responsiveness") OR TITLE-ABS-KEY("airway hyper-responsiveness") OR TITLE-ABS-KEY("respiratory hyper responsiveness") OR TITLE-ABS-KEY("respiratory hyper-responsiveness") OR TITLE-ABS-KEY("wheez*")
5	TITLE-ABS-KEY("immediate hypersensitiv*") OR TITLE-ABS-KEY("delayed hypersensitiv*") OR TITLE-ABS-KEY("IgE-mediated hypersensitiv*") OR TITLE-ABS-KEY("type I hypersensitiv*") OR TITLE-ABS-KEY("type IV hypersensitiv*") OR TITLE-ABS-KEY("atopic sensitization") OR TITLE-ABS-KEY("atop*") OR TITLE-ABS-KEY("allergic sensitization") OR TITLE-ABS-KEY("allergic disease") OR TITLE-ABS-KEY("allerg*")
6	TITLE-ABS-KEY("atopic dermatitis") OR TITLE-ABS-KEY("dermatitis") OR TITLE-ABS-KEY("atopic eczema") OR TITLE-ABS-KEY("eczema") OR TITLE-ABS-KEY("neurodermatitis*") OR TITLE-ABS-KEY("besnier's prurigo") OR TITLE-ABS-KEY("besniers prurigo") OR TITLE-ABS-KEY("besnier prurigo") OR TITLE-ABS-KEY("quincke's edema") OR TITLE-ABS-KEY("quinckes edema") OR TITLE-ABS-KEY("quincke edema") OR TITLE-ABS-KEY("angioneurotic edema") OR TITLE-ABS-KEY("hives") OR TITLE-ABS-KEY("anaphyla*") OR TITLE-ABS-KEY("urticari*")

7	TITLE-ABS-KEY("food hypersensitivit*") OR TITLE-ABS-KEY("food allerg*") OR TITLE-ABS-KEY("egg allerg*") OR TITLE-ABS-KEY("egg hypersensitivit*") OR TITLE-ABS-KEY("milk allerg*") OR TITLE-ABS-KEY("milk hypersensitivit*") OR TITLE-ABS-KEY("shellfish allerg*") OR TITLE-ABS-KEY("shellfish hypersensitivit*") OR TITLE-ABS-KEY("wheat allerg*") OR TITLE-ABS-KEY("wheat hypersensitivit*") OR TITLE-ABS-KEY("nut allerg*") OR TITLE-ABS-KEY("nut hypersensitivit*") OR TITLE-ABS-KEY("peanut allerg*") OR TITLE-ABS-KEY("peanut hypersensitivit*") OR TITLE-ABS-KEY("groundnut allerg*") OR TITLE-ABS-KEY("groundnut hypersensitivit*")
8	TITLE-ABS-KEY("allergic rhinoconjunctiviti*") OR TITLE-ABS-KEY("rhinoconjunctiviti*") OR TITLE-ABS-KEY("seasonal allergic rhiniti*") OR TITLE-ABS-KEY("perennial allergic rhiniti*") OR TITLE-ABS-KEY("allergic rhiniti*") OR TITLE-ABS-KEY("rhiniti*") OR TITLE-ABS-KEY("allergic conjunctiviti*") OR TITLE-ABS-KEY("vernal keratoconjunctiviti*") OR TITLE-ABS-KEY("vernal conjunctiviti*") OR TITLE-ABS-KEY("giant papillary conjunctiviti*") OR TITLE-ABS-KEY("hay fever") OR TITLE-ABS-KEY("hayfever") OR TITLE-ABS-KEY("pollinosis") OR TITLE-ABS-KEY("pollenosis") OR TITLE-ABS-KEY("nasal catarrh*")
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
<p>Full query</p> <p>(TITLE-ABS-KEY("birth order*") OR TITLE-ABS-KEY("multiple birth*") OR TITLE-ABS-KEY("birth rank*") OR TITLE-ABS-KEY("parity") OR TITLE-ABS-KEY("family characteristic*") OR TITLE-ABS-KEY("family size*") OR TITLE-ABS-KEY("family structure*") OR TITLE-ABS-KEY("family demograph*") OR TITLE-ABS-KEY("family composition") OR TITLE-ABS-KEY("household size*") OR TITLE-ABS-KEY("household demograph*") OR TITLE-ABS-KEY("household composition*") OR TITLE-ABS-KEY("sibling relation*") OR TITLE-ABS-KEY("sibling*") OR TITLE-ABS-KEY("brother*") OR TITLE-ABS-KEY("sister*") OR TITLE-ABS-KEY("sibship size*") OR TITLE-ABS-KEY("sibship*")) AND (TITLE-ABS-KEY("bronchial asthma*") OR TITLE-ABS-KEY("exercise-induced asthma*") OR TITLE-ABS-KEY("asthma*") OR TITLE-ABS-KEY("exercise-induced bronchospasm*") OR TITLE-ABS-KEY("respiratory hypersensitivit*") OR TITLE-ABS-KEY("airway hyper responsiveness") OR TITLE-ABS-KEY("airway hyper-responsiveness") OR TITLE-ABS-KEY("respiratory hyper responsiveness") OR TITLE-ABS-KEY("respiratory hyper-responsiveness") OR TITLE-ABS-KEY("wheez*") OR TITLE-ABS-KEY("immediate hypersensitivit*") OR TITLE-ABS-KEY("delayed hypersensitivit*") OR TITLE-ABS-KEY("IgE-mediated hypersensitivit*") OR TITLE-ABS-KEY("type I hypersensitivit*") OR TITLE-ABS-KEY("type IV hypersensitivit*") OR TITLE-ABS-KEY("atopic sensitization") OR TITLE-ABS-KEY("atop*") OR TITLE-ABS-KEY("allergic sensitization") OR TITLE-ABS-KEY("allergic disease") OR TITLE-ABS-KEY("allerg*") OR TITLE-ABS-KEY("atopic dermatitis") OR TITLE-ABS-KEY("dermatitis") OR TITLE-ABS-KEY("atopic eczema") OR TITLE-ABS-KEY("eczema") OR TITLE-ABS-KEY("neurodermatitis*") OR TITLE-ABS-KEY("besnier's prurigo") OR TITLE-ABS-KEY("besniers prurigo") OR TITLE-ABS-KEY("besnier prurigo") OR TITLE-ABS-KEY("quincke's edema") OR TITLE-ABS-KEY("quinckes edema") OR TITLE-ABS-KEY("quincke edema") OR TITLE-ABS-KEY("angioneurotic edema") OR TITLE-ABS-KEY("hives") OR TITLE-ABS-KEY("anaphyla*") OR TITLE-ABS-KEY("urticari*") OR TITLE-ABS-KEY("food hypersensitivit*") OR TITLE-ABS-KEY("food allerg*") OR TITLE-ABS-KEY("egg allerg*") OR TITLE-ABS-KEY("egg hypersensitivit*") OR TITLE-ABS-KEY("milk allerg*") OR TITLE-ABS-KEY("milk hypersensitivit*") OR TITLE-ABS-KEY("shellfish allerg*") OR TITLE-ABS-KEY("shellfish</p>	

hypersensitivit*") OR TITLE-ABS-KEY("wheat allerg*") OR TITLE-ABS-KEY("wheat hypersensitivit*") OR TITLE-ABS-KEY("nut allerg*") OR TITLE-ABS-KEY("nut hypersensitivit*") OR TITLE-ABS-KEY("peanut allerg*") OR TITLE-ABS-KEY("peanut hypersensitivit*") OR TITLE-ABS-KEY("groundnut allerg*") OR TITLE-ABS-KEY("groundnut hypersensitivit*") OR TITLE-ABS-KEY("allergic rhinoconjunctiviti*") OR TITLE-ABS-KEY("rhinoconjunctiviti*") OR TITLE-ABS-KEY("seasonal allergic rhiniti*") OR TITLE-ABS-KEY("perennial allergic rhiniti*") OR TITLE-ABS-KEY("allergic rhiniti*") OR TITLE-ABS-KEY("rhiniti*") OR TITLE-ABS-KEY("allergic conjunctiviti*") OR TITLE-ABS-KEY("vernal keratoconjunctiviti*") OR TITLE-ABS-KEY("vernal conjunctiviti*") OR TITLE-ABS-KEY("giant papillary conjunctiviti*") OR TITLE-ABS-KEY("hay fever") OR TITLE-ABS-KEY("hayfever") OR TITLE-ABS-KEY("pollinosis") OR TITLE-ABS-KEY("pollenosis") OR TITLE-ABS-KEY("nasal catarrh*"))

TITLE-ABS-KEY = *title, abstract, keywords*

Web of Science

#	Search term(s)
1	TS="birth order*" OR TS="multiple birth*" OR TS="birth rank*" OR TS="parity"
2	TS="family characteristic*" OR TS="family size*" OR TS="family structure*" OR TS="family demograph*" OR TS="family composition" OR TS="household size*" OR TS="household demograph*" OR TS="household composition"
3	TS="sibling*" OR TS="sister*" OR TS="brother*" OR TS="sibship size*" OR TS="sibship*"
4	TS="bronchial asthma*" OR TS="exercise-induced asthma*" OR TS="exercise-induced bronchospasm*" OR TS="asthma*" OR TS="respiratory hypersensitivit*" OR TS="respiratory hyper-responsiveness*" OR TS="airway hyper responsiveness*" OR TS="airway hyper-responsiveness*" OR TS=wheez*
5	TS="immediate hypersensitivit*" OR TS="delayed hypersensitivit*" OR TS="IgE-mediated hypersensitivit*" OR TS="type I hypersensitivit*" OR TS="type IV hypersensitivit*" OR TS="hypersensitivit*" OR TS="atopic sensitization" OR TS="atop*" OR TS="allergic sensitization" OR TS="allergic disease*" OR TS="allerg*"
6	TS="atopic dermatitis" OR TS="dermatitis" OR TS="atopic eczema" OR TS="eczema" OR TS="neurodermatiti*" OR TS="besnier's prurigo" OR TS="besniers prurigo" OR TS="besnier prurigo" OR TS="urticari*" OR TS="anaphyla*" OR TS="quincke's edema" OR TS="quinckes edema" OR TS="quincke edema" OR TS="angioneurotic edema" OR TS="angioedema" OR TS="hives"
7	TS="food hypersensitivit*" OR TS="food allerg*" OR TS="egg allerg*" OR TS="egg hypersensitivit*" OR TS="milk allerg*" OR TS="milk hypersensitivit*" OR TS="shellfish allerg*" OR TS="shellfish hypersensitivit*" OR TS="wheat allerg*" OR TS="wheat hypersensitivit*" OR TS="nut allerg*" OR TS="nut hypersensitivit*" OR TS="peanut allerg*" OR TS="peanut hypersensitivit*" OR TS="groundnut allerg*" OR TS="groundnut hypersensitivit*"
8	TS="pollen allerg*" OR TS="allergic rhinoconjunctiviti*" OR TS="rhinoconjunctiviti*" OR TS="seasonal allergic rhiniti*" OR TS="perennial allergic rhiniti*" OR TS="allergic rhiniti*" OR TS="rhiniti*" OR TS="allergic conjunctiviti*" OR TS="vernal keratoconjunctiviti*" OR

	TS="vernal conjunctiviti*" OR TS="giant papillary conjunctiviti*" OR TS="hay fever" OR TS="hayfever" OR TS="pollinosis" OR TS="pollenosis" OR TS="nasal catarrh*"
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
Full query	
(TS="birth order*" OR TS="multiple birth*" OR TS="birth rank*" OR TS="parity" OR TS="family characteristic*" OR TS="family size*" OR TS="family structure*" OR TS="family demograph*" OR TS="family composition" OR TS="household size*" OR TS="household demograph*" OR TS="household composition" OR TS="sibling*" OR TS="sister*" OR TS="brother*" OR TS="sibship size*" OR TS="sibship*") AND (TS="bronchial asthma*" OR TS="exercise-induced asthma*" OR TS="exercise-induced bronchospasm*" OR TS="asthma*" OR TS="respiratory hypersensitivit*" OR TS="respiratory hyper-responsiveness*" OR TS="airway hyper responsiveness*" OR TS="airway hyper-responsiveness*" OR TS="wheez*" OR TS="immediate hypersensitivit*" OR TS="delayed hypersensitivit*" OR TS="IgE-mediated hypersensitivit*" OR TS="type I hypersensitivit*" OR TS="type IV hypersensitivit*" OR TS="hypersensitivit*" OR TS="atopic sensitization" OR TS="atop*" OR TS="allergic sensitization" OR TS="allergic disease*" OR TS="allerg*" OR TS="atopic dermatitis" OR TS="dermatitis" OR TS="atopic eczema" OR TS="eczema" OR TS="neurodermatiti*" OR TS="besnier's prurigo" OR TS="besniers prurigo" OR TS="besnier prurigo" OR TS="urticari*" OR TS="anaphyla*" OR TS="quincke's edema" OR TS="quinckes edema" OR TS="quincke edema" OR TS="angioneurotic edema" OR TS="angioedema" OR TS="hives" OR TS="food hypersensitivit*" OR TS="food allerg*" OR TS="egg allerg*" OR TS="egg hypersensitivit*" OR TS="milk allerg*" OR TS="milk hypersensitivit*" OR TS="shellfish allerg*" OR TS="shellfish hypersensitivit*" OR TS="wheat allerg*" OR TS="wheat hypersensitivit*" OR TS="nut allerg*" OR TS="nut hypersensitivit*" OR TS="peanut allerg*" OR TS="peanut hypersensitivit*" OR TS="groundnut allerg*" OR TS="groundnut hypersensitivit*" OR TS="pollen allerg*" OR TS="allergic rhinoconjunctiviti*" OR TS="rhinoconjunctiviti*" OR TS="seasonal allergic rhiniti*" OR TS="perennial allergic rhiniti*" OR TS="allergic rhiniti*" OR TS="rhiniti*" OR TS="allergic conjunctiviti*" OR TS="vernal keratoconjunctiviti*" OR TS="vernal conjunctiviti*" OR TS="giant papillary conjunctiviti*" OR TS="hay fever" OR TS="hayfever" OR TS="pollinosis" OR TS="pollenosis" OR TS="nasal catarrh*")	

TS = title, abstract, author keywords, Keywords Plus

Appendix to

Sibship Size, Birth Order and Risk of Asthma and Allergy: Protocol for a Systematic Review and Meta-Analysis

Daniil Lisik, Saliha Selin Özüygür Ermis, Emma Goksör, Göran Wennergren, Bright I Nwaru

Appendix 2: Data Extraction Form

Reviewer (initials)	
Date of data extraction (yyyy-mm-dd)	
General information	
Author (for first author: surname, given name(s))	
Title of article	
Year of publication	
Country of origin of study	
Contact information to author(s)	
Study characteristics	
Study design	
Study aims/objectives	
Exposure(s) (for each exposure: 1) method(s) of assessment; 2) objectivity of assessment (objective/subjective ¹); 3) validity (yes ² /no); 4) reliability (yes ³ /no))	
Outcome(s) (for each outcome: 1) method(s) of assessment; 2) objectivity (objective/subjective ⁴); 3) validity (yes ² /no); 4) reliability (yes ³ /no))	
Follow-up (method; length)	Method: ; Length: Or: <input type="checkbox"/> not applicable
Study was conducted during (year(s))	
Participant selection	
Inclusion criteria	
Exclusion criteria	
Source(s) of subjects	
Population characteristics	
Participants recruited (n; details)	n: ; Details:

Participants eligible (n; % of “Participants recruited”; eligibility criteria)	n: ; % of “Participants recruited”: %; Eligibility criteria:
Participants included (n; % of “Participants eligible”)	n: ; % of “Participants eligible”: % Or:
Participants completing follow-up (n; % of “Participants included”)	n: ; % of “Participants included”: % Or:
Participants lost (n; % of “Participants included”; details; how it was dealt with)	n: ; % of “Participants included”: %; Details: ; How it was dealt with: Or:
Data lost (n; % of “Participants included”; details; how it was dealt with)	n: ; % of “Participants included”: %; Details: ; How it was dealt with:
Participants characteristics (for each group: 1) n_{total} ; 2) age (mean (SD)); 3) gender distribution (n_{males} (% of n_{total})); 4) ethnicity; 5) country; 6) economic classification of country by the World Bank; 7) setting; 8) co-morbidity)	
Results	
Outcomes (for each outcome for each exposure, stratified by group ⁵ if applicable: 1) n (% of n_{group}); 2) effect size (measure of effect) 95% CI; 3) p-value)	
Analysis	
Statistical analysis method	
Confounders (what confounders were identified; how they were controlled for; % of confounders controlled for)	Confounders identified: ; How they were controlled for: % of confounders controlled for:
Free-text interpretation of findings/conclusion	
Generalizability (is it likely that individuals selected for this study to be representative of the target population?)	
Miscellaneous	

Other comments/notes	
Quality assessment (based on the Effective Public Health Practice Project (EPHPP) quality assessment tool⁶)	
(A) Selection bias	
(Q1) Is it likely that individuals selected for this study to be representative of the target population?	
(Q2) How many of eligible individuals agreed to participate in the study? (%)	
Section rating	
(B) Study design	
Indicate the design of the study	
Was the study setting randomized? If “No”, go to (C)	
If “Yes”, was the randomization method described?	
If “Yes”, was the method referred to above appropriate?	
Section rating Rate longitudinal studies as “moderate”, and cross-sectional studies as “weak”	
(C) Confounders	
(Q1) Did the groups have significant differences in relation to each other prior to the intervention?	
(Q2) If “Yes”, indicate how many relevant confounders that were controlled for in any way (e.g. in study design through matching, stratification, or in analysis) (%)	
Section rating Rate studies without a control group as weak	
(D) Blinding	
(Q1) Did the outcome assessor(s) know about the exposure status of the participants?	
(Q2) Did the participants of the study know about the research question?	
Section rating Rate as “weak” if Q1 is 1 and Q2 is 3	
(E) Data collection methods	
(Q1) Were the tools used for data collection shown to be valid?	

(Q2) Were the tools used for data collection shown to be reliable?	
Section rating	
(F) Withdrawals and drop-outs	
(Q1) Did numbers and/or reasons for withdrawals and drop-outs per group get documented?	
(Q2) How many participants completed the study (if the value is different between groups, state the lowest)? (%)	
Section rating	
Global rating	
Did the two reviewers give different section ratings for A-F?	
If "Yes", what is the reason for the difference(s)?	
Final rating of both reviewers	

¹ Objective: medical records/official statistics. Subjective: self-report, observation.

² Yes: The assessment gives usable, meaningful information for the research question.

³ Yes: Results from assessment type are consistent and stable.

⁴ Objective: ICD code, verified diagnosis based on medical examination. Subjective: otherwise observed or self-reported symptoms/disease.

⁵ Applicable if specific stratification has been made in the analysis, e.g. significant differences and/or calculations based on gender of participants.

⁶ Modified version of EPHPP [1]. Original tool is available at: <https://www.ephpp.ca/quality-assessment-tool-for-quantitative-studies/>. The questions and answer alternatives are modified in phrasing for readability and the nature of relevant studies. Modifications of rating are clarified in green text above, based on the modifications of EPHPP done in a systematic review by Smith et al. in 2017 [2].

References

1. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. *J Eval Clin Pract.* 2012;18(1):12-18.
2. Smith M, Hosking J, Woodward A, Witten K, MacMillan A, Field A, et al. Systematic literature review of built environment effects on physical activity and active transport – an update and new findings on health equity. *International Journal of Behavioral Nutrition and Physical Activity.* 2017;14(1):158.

Appendix to

Sibship Size, Birth Order and Risk of Asthma and Allergy: Protocol for a Systematic Review and Meta-Analysis

Daniil Lisik, Saliha Selin Özüygür Ermis, Emma Goksör, Göran Wennergren, Bright I Nwaru

Appendix 3: PRISMA-P Checklist

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on page
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2, 4 (awaiting registration number)
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	9-10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	10
Sponsor	5b	Provide name for the review funder and/or sponsor	N/A
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	N/A
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	2-3
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	3-4

METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4-5
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	5-6
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	5-6, Appendix 1
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	6
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	6
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	6-7, Appendix 2
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	7
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	4-5
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	7
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	7-8
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	7-8
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	8
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	7
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	8
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	8

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items.**

1
2
3 **Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P**
4 **(including checklist) is held by the PRISMA-P Group and is distributed under a Creative**
5 **Commons Attribution Licence 4.0.**
6
7

8 *From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P*
9 *Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015:*
10 *elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Sibship Size, Birth Order and Risk of Asthma and Allergy: Protocol for a Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045795.R1
Article Type:	Protocol
Date Submitted by the Author:	30-Jul-2021
Complete List of Authors:	Lisik, Daniil; University of Gothenburg, Krefting Research Centre Ioannidou, Athina; University of Gothenburg Milani, Gregorio; Ospedale Maggiore Policlinico, Pediatric unit Nyassi, Sungkutu; University of Gothenburg Özuygur Ermis, Saliha Selin; Dokuz Eylül University, Department of Pulmonology Spolidoro, Giulia C. I.; University of Milan, Department of Clinical Sciences and Community Health Goksör, Emma; University of Gothenburg Wennergren, Göran; University of Gothenburg Sahlgrenska Academy, Krefting Research Centre; University of Gothenburg Sahlgrenska Academy, Dept of Paediatrics Nwaru, Bright; University of Gothenburg, Krefting Research Centre
Primary Subject Heading:	Immunology (including allergy)
Secondary Subject Heading:	Epidemiology
Keywords:	Asthma < THORACIC MEDICINE, Allergy < THORACIC MEDICINE, Eczema < DERMATOLOGY, IMMUNOLOGY, Paediatric infectious disease & immunisation < PAEDIATRICS, Paediatric dermatology < PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Sibship Size, Birth Order and Risk of Asthma and Allergy: Protocol for a Systematic Review and Meta-Analysis

Daniil Lisik³, Athina Ioannidou³, Gregorio Paolo Milani⁴, Sungkutu Nyassi³, Saliha Selin Özüygür Ermis¹, Giulia Spolidoro⁴, Emma Goksör², Göran Wennergren², Bright I Nwaru³

Author affiliations

¹ Department of Pulmonology, Dokuz Eylul University, Izmir, Turkey

² Department of Pediatrics, University of Gothenburg, Queen Silvia Children's Hospital, Gothenburg, Sweden.

³ Krefling Research Centre, Institute of Medicine, University of Gothenburg, Sweden

⁴ Department of Clinical Sciences and Community Health, Università degli Studi di Milano Statale, Italy

Correspondence to

Daniil Lisik

Institute of Medicine

Sahlgrenska Academy

University of Gothenburg, Sweden

daniil.lisik@gmail.com

ABSTRACT

Introduction: The hygiene hypothesis suggests that reduced exposure to microbes might have contributed to the increase in prevalence and incidence of asthma and allergy observed during the second half of the last century. Following this proposal, several studies have investigated the role of sibship size and birth order in the development of asthma and allergic diseases, but the underlying evidence is conflicting. The objective of the present systematic review will be to identify, critically appraise and synthesize previous primary studies investigating the association of sibship size and birth order with the risk of asthma and allergic diseases.

Methods and analysis: The following databases will be searched: AMED, CABI, CINAHL, Embase, Google Scholar, OAIster, Open Access Theses and Dissertations, Open Grey,

1
2
3 ProQuest Dissertations & Theses Global, PsycINFO, PubMed, SciELO, Scopus, Web of
4 Science, and WHO Global Index Medicus. Studies published up until 31st December 2020
5 will be eligible. There will be no restrictions by language and geographical location. Risk of
6 bias in the included studies will be assessed using the Effective Public Health Practice Project
7 (EPHPP) quality assessment tool. The produced evidence will be synthesized narratively, and
8 studies that present comparable numerical data will be included in meta-analyses using
9 random-effects model.

10
11
12
13
14
15 **Ethics and dissemination:** Only data from the published literature will be included in this
16 systematic review. Therefore, no ethical approval is required. The final review paper will be
17 published in a peer-reviewed journal.

18
19
20
21 **PROSPERO registration number:** CRD42020207905.

22 23 24 25 26 **Strengths and limitations of this study**

- 27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
- This will be the first systematic review encompassing a comprehensive spectrum of the most common allergic and respiratory outcomes, in relation to sibship size and birth order.
- Inclusion of the leading databases, including search of the gray literature, enables a comprehensive identification of the relevant studies addressing the research question.
- The reproducibility of our work is enhanced through a priori outline of the review processes before the actual review starts.
- Self-reported diagnoses of the study outcomes are expected to make up a significant source of data from included studies, which gives the possibility of assessment bias.

51 52 53 54 55 56 57 58 59 60 **INTRODUCTION**

The incidence and prevalence of asthma, along with allergic diseases such as allergic rhinitis and atopic eczema, were observed to have increased during the second half of the last century, in particular in the developed world [1, 2]. More recent trends remain unclear, as both increase [3] and leveling off [1, 4, 5] have been suggested. Around 300 million people

1
2
3 have asthma globally [1]. For allergic diseases, evidence indicates that there is still a global
4 increase in prevalence [5, 6]. Asthma and allergic diseases account for significant morbidity
5 for individuals, as well as a substantial socio-economic burden on the society [2]. Asthma
6 results in roughly 14 million missed school days each year in the United States alone, and the
7 morbidity is even higher for adults [7]. Allergic rhinitis is also associated with significant loss
8 in productivity [8]. Furthermore, the World Health Organization estimates that roughly
9 250,000 cases of death annually, worldwide, are due to asthma [7]. Identifying risk factors
10 for asthma and allergy is therefore of great interest, in order to reduce the burden associated
11 with these diseases.
12
13
14
15
16
17
18
19

20 Over the last five decades, numerous hypotheses have been proposed to explain the observed
21 increase in the prevalence of these diseases, a substantial part of the studies focusing on the
22 role of environmental factors. One of the main hypotheses is the hygiene hypothesis, which
23 was first proposed by Strachan in 1989, and suggests that reduced microbial exposure during
24 childhood increases the risk of developing asthma and allergy [9]. One of the first proposed
25 underlying biological mechanisms to the hygiene hypothesis was the observed skewing of
26 balance towards T helper 2 cells (which have been associated with allergic sensitization) in
27 subjects lacking microbial stimuli, and conversely a T helper 1 cell domination in subjects
28 exposed to greater quantities of microbes [10]. Further research has broadened the
29 explanatory model with additional factors, such as T regulatory cells and T helper 17 cells
30 [11], but the pathophysiology is yet to be fully understood [12]. Connected to the hygiene
31 hypothesis is the proposed sibling effect, which suggests that the number of siblings and/or
32 the birth order of a child in a family may play a role in the development of asthma and
33 allergy, as a result of varying degrees of microbial exposure during childhood, depending on
34 the number of siblings in total and/or the number of younger/older siblings [13].
35
36
37
38
39
40
41
42
43
44
45
46
47

48 While several studies have investigated the association of sibship (group of individuals
49 sharing the same pair of parents) size and birth order (the sequence in which members of a
50 sibship are born) with risk of asthma and allergic diseases, findings are conflicting [14].
51 Karmaus and Botezan have estimated the proportion of cases attributable to the sibling effect
52 to be 34% for atopic dermatitis, 56% for allergic rhinitis, and 28% for asthma. Karmaus and
53 Botezan have also argued that at least 30% of cases of asthma and allergy could be prevented
54
55
56
57
58
59
60

1
2
3 if the causal factors for these conditions were better understood [15], further indicating
4 warranty for elucidating the sibling effect in relation to asthma and allergy. So far, there are
5 no systematic reviews synthesizing evidence from previous studies on the topic. A systematic
6 synthesis of previous studies investigating the association of sibship size and birth order with
7 risk of asthma and allergy will provide a clearer appreciation of the strength, magnitude, and
8 quality of the underlying evidence.
9
10
11
12
13
14

15 **Aim**

16
17 To identify, critically appraise and synthesize previous primary studies investigating the
18 association of sibship size and birth order with risk of asthma and allergic diseases.
19
20
21
22

23 **METHODS AND ANALYSES**

24
25 This protocol is reported according to the recommendations of the Preferred Reporting Items
26 for Systematic Reviews and Meta-Analysis Protocol (PRISMA-P) [16], which provides
27 guidelines for a standardized, transparent and reproducible reporting of systematic review
28 protocols. The PRISMA-P checklist is presented in Appendix 1. Updates to the protocol will
29 be documented, and deviations from the protocol will be described in the final review paper.
30
31 The protocol for this systematic review has been prospectively registered with the
32 international prospective register of systematic reviews (PROSPERO,
33 https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=207905) with
34 registration number CRD42020207905.
35
36
37
38
39
40
41
42

43 **Study eligibility criteria**

44 **Study types and publication status**

45
46 We will include observational epidemiological studies, including prospective and
47 retrospective cohort studies, case-control studies, and cross-sectional studies. Randomized
48 controlled studies, quasi-randomized controlled studies, controlled before-after studies, and
49 controlled clinical trials will not be considered, as interventional studies are not relevant for
50 this research question. Animal studies, reviews, case studies, case series, expert opinions will
51 also be excluded. Studies of any publication status will be eligible, and data used from them
52 if available.
53
54
55
56
57
58
59
60

Participants

Offspring of any age, gender, ethnic background and medical background, where the study context is that the participants are part of defined sibships. Studies with any amount of participants will be eligible.

Exposures

Sibship size, birth order (number of older siblings), and number of younger siblings in the studied sibships.

Outcome measures

Self-reported or objectively measured/diagnosed asthma and allergic disease in the sibships. For the purpose of encompassing all relevant literature on the topic, asthma and allergic disease will be defined broadly. Asthma will be defined as any type of asthma, including those based on symptom definition, such as wheezing, and those based on spirometry findings of variable expiratory airflow limitation [17]. Allergic disease will encompass any of the following: (a) allergic rhinitis/(rhino)conjunctivitis, food allergy, atopic eczema, urticaria, angioedema, anaphylaxis [18]; (b) indicators of hypersensitivity (and indirectly of allergic disease), which includes allergen-specific serum immunoglobulin E (IgE) test, skin prick test (SPT), provocation/challenge test. Conditions with primarily a genetic etiology, such as hereditary angioedema [19], will not be included in these definitions.

Search methods

The search queries were developed using the PEO model: population, exposure and outcome (PEO). PEO is a specific implementation of PICO, used as a framework to produce effective search queries from formulated research questions, especially befitting retrieval of interventional and observational studies [20]. Since the population (P) will be defined broadly, i.e., including both studies in children and adults, the actual search queries will be composed of two blocks; exposure (E) and outcome (O). A scoping search was performed in PubMed to identify previous studies on the topic and map relevant search terms. The search terms identified were: Medical Subject Headings (MeSH), and their corresponding alternatives in other databases; entry terms; free-text words and phrases. Subsequent scoping

1
2
3 searches were made in PubMed with boolean operator “NOT” between various MeSH and
4 free-text terms, alternately, in order to identify more synonyms and related search terms. The
5 developed search terms have been piloted and refined before they will be used to identify
6 relevant studies. The search queries have been modified for each database to be searched in
7 regards to, inter alia, support for controlled vocabulary and syntax. Peer Review of Electronic
8 Search Strategies (PRESS) has been used to identify potential weaknesses in the search
9 strategy. Details of the search strategy are presented in Appendix 2.
10
11
12
13
14
15
16

17 Studies will be retrieved from the following databases: AMED (via Ovid), CABI, CINAHL
18 (via EBSCO), Embase (via Ovid), Google Scholar, PsycINFO (via ProQuest), PubMed,
19 SciELO, Scopus, Web of Science, and WHO Global Index Medicus. In addition, unpublished
20 articles and gray literature will be retrieved through searches of OAster, Open Access
21 Theses and Dissertations, Open Grey, and ProQuest Dissertations & Theses Global. Finally,
22 studies will also be included from reference lists of the studies included in the review, as well
23 as through contact with experts who have published in the field. All databases will be
24 searched for articles published from inception of respective database up until 31st December
25 2020; an updated search will be performed at the completion of the review to ensure
26 inclusion of studies published after the first search. There will be no language restrictions,
27 and articles will be translated into English where possible. Articles that could not be
28 translated will be reported in the final review paper. In Google Scholar, due to the fact that
29 the amount of results is sometimes overwhelming, results will be retrieved from the first 300
30 hits [21]. Furthermore, the search query for Google Scholar has been significantly simplified,
31 including only the most important terms in each block, due to an upper limit of 256
32 characters for search strings [22].
33
34
35
36
37
38
39
40
41
42
43
44
45
46

47 **Data management**

48 EndNote will be used for de-duplication, full-text retrieval, secondary screening, and for
49 general management of retrieved studies. For primary screening, the articles will be imported
50 to Rayyan QCRI.
51
52
53
54

55 **Screening/selection process**

56
57
58
59
60

1
2
3 The first stage of screening will be based on the title and/or abstract of the articles. Articles
4 that are clearly not relevant to the research question or clearly meet any of the exclusion
5 criteria will be excluded. Articles, where there is doubt about relevancy, will be included to
6 the next step. In the second stage of screening, the full text of the articles will be retrieved
7 and assessed for eligibility. The reason for each article not being included will be
8 documented and presented in a PRISMA flow diagram in the final review paper [23]. The
9 screening/selection will be independently performed by two reviewers. A third reviewer will
10 arbitrate any disagreement.
11
12
13
14
15
16
17
18
19

20 **Data extraction**

21 A data extraction form (Appendix 3) has been developed to extract data from included
22 studies in a standardized and reproducible fashion. The form will be piloted and revised
23 before being used in the review. If a study does not present needed data, authors of the study
24 will be contacted. Extracted data will be presented in table form. The extraction will be
25 independently conducted by two reviewers. A third reviewer will arbitrate any disagreement.
26
27
28
29
30
31

32 **Data items**

33 The following data items will be summarized from each study: author of publication; country
34 of origin of study; publication year; type of study design; sample size of study; source from
35 where study participants were recruited; definition and assessment of sibship and birth order;
36 duration of follow-up; confounding factors adjusted included in studies; study outcomes and
37 their assessment; analysis methods; and main results.
38
39
40
41
42
43
44

45 **Quality assessment**

46 Quality and risk of bias in the individual, included studies will be assessed using the
47 Effective Public Health Practice Project Quality Assessment Tool (EPHPP) [24]. The EPHPP
48 contains six domains of assessment for each study, including study design, selection bias,
49 confounding, blinding, study collection, withdrawals and dropouts. Based on the grading of
50 each of the six domains, a global quality grading will be derived for each study. Detailed
51 results will be presented in a separate table in the final review paper. Appraisal of quality and
52
53
54
55
56
57
58
59
60

risk of bias will be independently performed by two reviewers. A third reviewer will arbitrate any disagreement.

Data synthesis

Descriptive tables will be generated to present the key characteristics of the included studies. The produced evidence will be synthesized narratively. In addition, studies that present numerically comparable and reasonably homogenous (in terms of clinical and epidemiological settings of study participants) data will be synthesized quantitatively with meta-analyses in RevMan 5, to produce pooled effect size estimates. Random-effects model will be applied in the meta-analyses, because the included studies, solely based on published literature, are anticipated to not be similar in every aspect and thus do not estimate the same effect. This model is more conservative and provides a realistic scenario in the context of studies gathered solely from published literature [25]. Separate meta-analyses will be undertaken for each of the factors investigate (sibship size and birth order) in relation to each asthma and allergy outcome. The results of the meta-analyses will be presented in forest plots.

Risk ratio (RR) will be used as the outcome measure in the meta-analyses, because of its intuitive interpretative feature [26]. Data from studies presenting effect measures as odds ratio (OR), incidence rate ratio (IRR), or hazard ratio (HR) will be converted to estimates of RR before combining with other studies, using the following formulas:

(a) $RR \approx IRR$;

(b) $RR \approx HR$ or OR (if outcome is < 15% by the end of follow-up);

(c) $RR \approx \sqrt{OR}$ or $\frac{1 - 0.5^{\sqrt{HR}}}{1 - 0.5^{\frac{1}{\sqrt{HR}}}}$ (if outcome is $\geq 15\%$ by the end of follow-up) [27]

Calculation of I^2 will quantify heterogeneity between the included studies [28]. Consideration will be taken, regarding that this statistic can be biased in meta-analyses with few studies [29]. Subgroup analysis will be performed to explore potential reasons for heterogeneity between studies with the following subgroup variables: (a) study design; (b) quality appraisal of studies; (c) classification of the study country into “high-income”, “upper-middle-income”, “lower-middle-income”, and “low-income” economy, as defined by the World Bank [30]; (d) time during which the study was conducted, grouped into <1990, 1990-1999, 2000-2009, and 2010-2020; (e) participant age, grouped arbitrarily into < 1 year, 1-6 years, 7-

1
2
3 14 years, ≥ 15 years; (f) gender, grouped into "male" and "female". Subgroup analysis will be
4 performed if there will be at least 4 (arbitrarily chosen cutoff [31]) studies in at least 2
5 subgroups. In addition, if more than 10 included studies present comparable numerical data
6 [32], meta-regression will be performed to explore the impact of explanatory variables
7 (covariates) on the observed heterogeneity in estimates across studies.
8
9
10
11
12

13 To investigate whether the conclusions of the review are independent of arbitrary decisions,
14 sensitivity-analysis will be performed by only including studies which (a) reach either
15 "strong" or "moderate" global rating of quality in accordance to EPHPP; (b) have objectively
16 verified diagnosis of asthma or allergic disease as outcome, with either ICD codes or verified
17 medical examination as the basis for diagnosis. The sensitivity analysis will be reported in a
18 summary table.
19
20
21
22
23
24
25

26 **Publication bias**

27
28 Publication bias will be assessed with Funnel plot, as well as Begg's rank test and Egger's
29 regression test [33, 34], with $p < 0.05$ being defined as statistically significant. In case of
30 (significant) publication bias, the trim-and-fill method will be implemented to analyze its
31 influence on the review results [35].
32
33
34
35
36

37 **Patient and public involvement**

38
39 No patients or participants were involved in the development of this protocol or the design of
40 this study.
41
42
43
44

45 **DISCUSSION**

46
47 The conclusions that will potentially be drawn from this systematic review, will be limited by
48 the quality of the included studies. For this research question, the fact that all included studies
49 will be observational limits the establishment of causality between sibship size, birth order,
50 and risk of asthma and allergic diseases [36].
51
52
53
54
55

56 A strength of this study is the comprehensiveness of the search strategy, including 15 of the
57 leading databases of formally published literature, as well as gray literature. There will be no
58
59
60

1
2
3 restrictions in terms of language or geographical location. All these enable comprehensive
4 identification of relevant studies for this research question. Furthermore, this systematic
5 review will encompass a comprehensive spectrum of the most common asthma and allergic
6 outcomes in relation to sibship size and birth order, thereby contributing to a broad overview
7 of the existing evidence on the topic.
8
9
10
11
12

13 Asthma and allergic diseases pose a significant burden on both individuals and society.
14 Whilst the role of sibship size and birth order in the development of these diseases have been
15 investigated in several studies, albeit with conflicting evidence, a systematic review of
16 existing studies is essential in providing a clearer appreciation of the underlying evidence.
17 This protocol presents the methodology to perform a comprehensive systematic review and
18 meta-analysis of existing literature on the topic.
19
20
21
22
23
24
25
26

27 **ETHICS AND DISSEMINATION**

28 Ethical approval will not be required due to the study being a systematic review of already
29 published primary studies available in the public domain. Furthermore, patient consent will
30 not be needed since data will stay aggregated [37, 38].
31
32
33
34
35

36 **CONTRIBUTIONS**

37 BIN conceived the study idea. DL wrote the protocol, with review and suggestions for improvement from BIN,
38 EG, GW, and SSÖE. All authors (AI, BIN, DL, EG, GPM, GS, GW, SN, and SSÖE) commented and approved
39 the last version being submitted.
40
41
42
43
44

45 **FUNDING**

46 There was no specific funding for this paper.
47
48
49
50

51 **COMPETING INTERESTS**

52 None declared.
53
54
55
56
57
58
59
60

REFERENCES

1. Dharmage SC, Perret JL, Custovic A. Epidemiology of Asthma in Children and Adults. *Front Pediatr*. 2019;7:246.
2. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma Res Pract*. 2017;3:1.
3. Lundbäck B, Backman H, Lötvall J, Rönmark E. Is asthma prevalence still increasing? *Expert Rev Respir Med*. 2016;10(1):39-51.
4. Martinez FD. Trends in asthma prevalence, admission rates, and asthma deaths. *Respir Care*. 2008;53(5):561-565; discussion 565-567.
5. Hicke-Roberts A, Åberg N, Wennergren G, Hesselmar B. Allergic rhinoconjunctivitis continued to increase in Swedish children up to 2007, but asthma and eczema levelled off from 1991. *Acta Paediatr*. 2017;106(1):75-80.
6. Doll RJ, Joseph NI, McGarry D, Jhaveri D, Sher T, Hostoffer R. *Epidemiology of Allergic Diseases. Allergy and Asthma: The Basics to Best Practices*. Cham: Springer International Publishing; 2019. p. 31-51.
7. Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. *World Allergy Organ J*. 2014;7(1):12.
8. Bousquet J, Khaltaev N, Cruz AA, Denburg J, Fokkens WJ, Togias A, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). *Allergy*. 2008;63 Suppl 86:8-160.
9. Strachan DP. Hay fever, hygiene, and household size. *BMJ (Clinical research ed)*. 1989;299(6710):1259-1260.
10. Pfefferle PI, Teich R, Renz H. *The Immunological Basis of the Hygiene Hypothesis*. Springer Japan. p. 325-348.
11. Stiemsma LT, Reynolds LA, Turvey SE, Finlay BB. The hygiene hypothesis: current perspectives and future therapies. *Immunotargets Ther*. 2015;4:143-157.
12. Lambrecht BN, Hammad H. The immunology of the allergy epidemic and the hygiene hypothesis. *Nature Immunology*. 2017;18(10):1076-1083.
13. Bloomfield SF, Rook GA, Scott EA, Shanahan F, Stanwell-Smith R, Turner P. Time to abandon the hygiene hypothesis: new perspectives on allergic disease, the human microbiome, infectious disease prevention and the role of targeted hygiene. *Perspect Public Health*. 2016;136(4):213-224.
14. Goldberg S, Israeli E, Schwartz S, Shochat T, Izbicki G, Toker-Maimon O, et al. Asthma prevalence, family size, and birth order. *Chest*. 2007;131(6):1747-1752.
15. Karmaus W. Does a higher number of siblings protect against the development of allergy and asthma? A review. *Journal of Epidemiology & Community Health*. 2002;56(3):209-217.
16. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*. 2015;4(1):1.
17. Zeller TA. Respiratory Conditions Update: Asthma. *FP Essent*. 2016;448:11-19.
18. Pinart M, Albang R, Maier D, Duran-Tauleria E, Mena G, Gimeno-Santos E, et al. Systematic Review on the Definition of Allergic Diseases in Children: The MeDALL Study. *International Archives of Allergy and Immunology*. 2015;168(2):110-121.
19. Banerji A. Hereditary angioedema: classification, pathogenesis, and diagnosis. *Allergy Asthma Proc*. 2011;32(6):403-407.
20. Khan KS, Kunz R, Kleijnen J, Antes G. Five steps to conducting a systematic review. *J R Soc Med*. 2003;96(3):118-121.
21. Haddaway NR, Collins AM, Coughlin D, Kirk S. The Role of Google Scholar in Evidence Reviews and Its Applicability to Grey Literature Searching. *PLOS ONE*. 2015;10(9):e0138237.

- 1
2
3 22. Gusenbauer M, Haddaway NR. Which academic search systems are suitable for systematic reviews or meta-analyses?
4 Evaluating retrieval qualities of Google Scholar, PubMed, and 26 other resources. *Research Synthesis Methods*.
5 2020;11(2):181-217.
6
7 23. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting
8 systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *Bmj*.
9 2009;339:b2700.
10
11 24. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews:
12 a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality
13 Assessment Tool: methodological research. *J Eval Clin Pract*. 2012;18(1):12-18.
14
15 25. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models
16 for meta-analysis. *Res Synth Methods*. 2010;1(2):97-111.
17
18 26. Davies HT, Crombie IK, Tavakoli M. When can odds ratios mislead? *Bmj*. 1998;316(7136):989-991.
19
20 27. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. *Ann Intern Med*.
21 2017;167(4):268-274.
22
23 28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *Bmj*.
24 2003;327(7414):557-560.
25
26 29. von Hippel PT. The heterogeneity statistic I(2) can be biased in small meta-analyses. *BMC Med Res Methodol*.
27 2015;15:35.
28
29 30. World Bank. World Bank country and lending groups. Washington (DC): World Bank; 2020 [cited 2020 Sept 6].
30 Available from: <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519>.
31
32 31. Fu R, Gartlehner G, Grant M, Shamliyan T, Sedrakyan A, Wilt TJ, et al. AHRQ Methods for Effective Health Care
33 Conducting Quantitative Synthesis When Comparing Medical Interventions: AHRQ and the Effective Health Care Program.
34 Methods Guide for Effectiveness and Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare
35 Research and Quality (US); 2008.
36
37 32. Schmid CH, Stark PC, Berlin JA, Landais P, Lau J. Meta-regression detected associations between heterogeneous
38 treatment effects and study-level, but not patient-level, factors. *Journal of Clinical Epidemiology*. 2004;57(7):683-697.
39
40 33. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *Bmj*.
41 1997;315(7109):629-634.
42
43 34. Lin L, Chu H. Quantifying publication bias in meta-analysis. *Biometrics*. 2018;74(3):785-794.
44
45 35. Shi L, Lin L. The trim-and-fill method for publication bias: practical guidelines and recommendations based on a large
46 database of meta-analyses. *Medicine (Baltimore)*. 2019;98(23):e15987.
47
48 36. Petrisor B, Bhandari M. The hierarchy of evidence: Levels and grades of recommendation. *Indian J Orthop*.
49 2007;41(1):11-15.
50
51 37. Wormald R, Evans J. What Makes Systematic Reviews Systematic and Why are They the Highest Level of Evidence?
52 *Ophthalmic Epidemiology*. 2018;25(1):27-30.
53
54 38. Suri H. Ethical Considerations of Conducting Systematic Reviews in Educational Research. In: Zawacki-Richter O,
55 Kerres M, Bedenlier S, Bond M, Buntins K, editors. *Systematic Reviews in Educational Research: Methodology,*
56 *Perspectives and Application*. Wiesbaden: Springer Fachmedien Wiesbaden; 2020. p. 41-54.
57
58
59
60

Appendix to

Sibship Size, Birth Order and Risk of Asthma and Allergy: Protocol for a Systematic Review and Meta-Analysis

Daniil Lisik, Athina Ioannidou, Gregorio Paolo Milani, Sungkutu Nyassi, Saliha Selin Özüygür Ermis, Giulia Spolidoro, Emma Goksör, Göran Wennergren, Bright I Nwaru

Appendix 1: PRISMA-P Checklist

PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol*

Section and topic	Item No	Checklist item	Reported on page
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	N/A
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2, 4 (PROSPERO, registration number CRD420202079 05)
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	N/A
Support:			
Sources	5a	Indicate sources of financial or other support for the review	10
Sponsor	5b	Provide name for the review funder and/or sponsor	N/A
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	N/A
INTRODUCTION			

Rationale	6	Describe the rationale for the review in the context of what is already known	2-4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	3-4
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4-5
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	5-6, Appendix 1
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	6
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	6-7
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	7, Appendix 2
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	7
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	5
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	9
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	8
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I^2 , Kendall's τ)	8
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	8-9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	8

Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	9

*** It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.

Appendix to

Sibship Size, Birth Order and Risk of Asthma and Allergy: Protocol for a Systematic Review and Meta-Analysis

Daniil Lisik, Athina Ioannidou, Gregorio Paolo Milani, Sungkutu Nyassi, Saliha Selin Özüygür Ermis, Giulia Spolidoro, Emma Goksör, Göran Wennergren, Bright I Nwaru

Appendix 2: Search Strategies

Colorization

Red: controlled vocabulary/thesaurus

Blue: free-text

Green: referral to search query component (table row; #)

AMED

#	Search term(s)
1	(birth order* or birth rank* or multiple birth* or parity).mp.
2	exp Family Characteristics/ or (family characteristic* or family size* or family structure* or family demograph* or family composition or household size* or household demograph* or household composition).mp.
3	exp Sibling Relations/ or (sibling* or sister* or brother* or sibship size* or sibship*).mp.
4	or/1-3
5	exp Asthma/ or (bronchial asthma* or exercise-induced asthma* or exercise-induced bronchospasm* or asthma* or respiratory hypersensitiv* or airway hyper responsiveness or airway hyper-responsiveness or respiratory hyper responsiveness or respiratory hyper-responsiveness or wheez*).mp.
6	exp Hypersensitivity/ or exp Hypersensitivity Immediate/ or exp Hypersensitivity Delayed/ or (immediate hypersensitiv* or delayed hypersensitiv* or IgE-mediated hypersensitiv* or type I hypersensitiv* or type IV hypersensitiv* or atopic sensitization or atop* or allergic sensitization or allerg*).mp.
7	exp Dermatitis/ or exp Anaphylaxis/ or (atopic dermatitis or dermatitis or neurodermatiti* or besniers prurigo or besnier prurigo or atopic eczema or eczema or urticari* or anaphyla* or quinckes edema or quincke edema or angioneurotic edema or angioedema or hives).mp.
8	exp Food Hypersensitivity/ or (food hypersensitiv* or food allerg* or egg hypersensitiv* or egg allerg* or milk hypersensitiv* or milk allerg* or shellfish hypersensitiv* or shellfish allerg* or wheat hypersensitiv* or wheat allerg* or nut hypersensitiv* or nut allerg* or peanut hypersensitiv* or peanut allerg* or groundnut hypersensitiv* or groundnut allerg*).mp.

9	exp Rhinitis/ or exp Conjunctivitis/ or (allergic rhinoconjunctiviti* or rhinoconjunctiviti* or allergic rhiniti* or seasonal allergic rhiniti* or perennial allergic rhiniti* or rhiniti* or allergic conjunctiviti* or vernal keratoconjunctiviti* or vernal conjunctiviti* or giant papillary conjunctiviti* or hay fever or hayfever or pollinosis or nasal catarrh*).mp.
10	or/5-9
11	4 and 10

Full query

((birth order* or birth rank* or multiple birth* or parity).mp. or exp Family Characteristics/ or (family characteristic* or family size* or family structure* or family demograph* or family composition or household size* or household demograph* or household composition).mp. or exp Sibling Relations/ or (sibling* or sister* or brother* or sibship size* or sibship*).mp.) and (exp Asthma/ or (bronchial asthma* or exercise-induced asthma* or exercise-induced bronchospasm* or asthma* or respiratory hypersensitiv* or airway hyper responsiveness or airway hyper-responsiveness or respiratory hyper responsiveness or respiratory hyper-responsiveness or wheez*).mp. or exp Hypersensitivity/ or exp Hypersensitivity Immediate/ or exp Hypersensitivity Delayed/ or (immediate hypersensitiv* or delayed hypersensitiv* or IgE-mediated hypersensitiv* or type I hypersensitiv* or type IV hypersensitiv* or atopic sensitization or atop* or allergic sensitization or allerg*).mp. or exp Dermatitis/ or exp Anaphylaxis/ or (atopic dermatitis or dermatitis or neurodermatiti* or besniers prurigo or besnier prurigo or atopic eczema or eczema or urticari* or anaphyla* or quinckes edema or quincke edema or angioneurotic edema or angioedema or hives).mp. or exp Food Hypersensitivity/ or (food hypersensitiv* or food allerg* or egg hypersensitiv* or egg allerg* or milk hypersensitiv* or milk allerg* or shellfish hypersensitiv* or shellfish allerg* or wheat hypersensitiv* or wheat allerg* or nut hypersensitiv* or nut allerg* or peanut hypersensitiv* or peanut allerg* or groundnut hypersensitiv* or groundnut allerg*).mp. or exp Rhinitis/ or exp Conjunctivitis/ or (allergic rhinoconjunctiviti* or rhinoconjunctiviti* or allergic rhiniti* or seasonal allergic rhiniti* or perennial allergic rhiniti* or rhiniti* or allergic conjunctiviti* or vernal keratoconjunctiviti* or vernal conjunctiviti* or giant papillary conjunctiviti* or hay fever or hayfever or pollinosis or nasal catarrh*).mp.)

exp = include all narrower subject headings; mp= abstract, heading words, title

CABI; OAIster; Open Access Theses and Dissertations; Open Grey; ProQuest
 Dissertations & Theses Global; SciELO; WHO Global Index Medicus

#	Search term(s)
1	"birth order" OR "multiple births" OR "birth rank" OR "parity"
2	"family characteristics" OR "family size" OR "family structure" OR "family demography" OR "family composition" OR "household size" OR "household demography" OR "household composition"
3	"siblings" OR "sibling relations" OR "sister" OR "brother" OR "sibship"
4	"exercise-induced bronchospasm" OR "asthma" OR "airway hyper-responsiveness" OR "respiratory hyper-responsiveness" OR "wheeze" OR "wheezing"
5	"hypersensitivity" OR "atopic sensitization" OR "atopy" OR "allergic sensitization" OR "allergic disease" OR "allergic condition" OR "allergy" OR "allergies"

6	"dermatitis" OR "eczema" OR "neurodermatitis" OR "besnier's prurigo" OR "urticaria" OR "anaphylaxis" OR "anaphylactic shock" OR "quincke's edema" OR "angionuerotic edema" OR "angioedema" OR "hives"
8	"rhinoconjunctivitis" OR "rhinitis" OR "allergic conjunctivitis" OR "vernal keratoconjunctivitis" OR "vernal conjunctivitis" OR "giant papillary conjunctivitis" OR "hay fever" OR "pollinosis" OR "pollenosis" OR "nasal catarrh"
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
Full query ("birth order" OR "multiple births" OR "birth rank" OR "parity" OR "family characteristics" OR "family size" OR "family structure" OR "family demography" OR "family composition" OR "household size" OR "household demography" OR "household composition" OR "siblings" OR "sibling relations" OR "sister" OR "brother" OR "sibship") AND ("exercise-induced bronchospasm" OR "asthma" OR "airway hyper-responsiveness" OR "respiratory hyper-responsiveness" OR "wheeze" OR "wheezing" OR "hypersensitivity" OR "atopic sensitization" OR "atopy" OR "allergic sensitization" OR "allergic disease" OR "allergic condition" OR "allergy" OR "allergies" OR "dermatitis" OR "eczema" OR "neurodermatitis" OR "besnier's prurigo" OR "urticaria" OR "anaphylaxis" OR "anaphylactic shock" OR "quincke's edema" OR "angionuerotic edema" OR "angioedema" OR "hives" OR "rhinoconjunctivitis" OR "rhinitis" OR "allergic conjunctivitis" OR "vernal keratoconjunctivitis" OR "vernal conjunctivitis" OR "giant papillary conjunctivitis" OR "hay fever" OR "pollinosis" OR "pollenosis" OR "nasal catarrh")	

CINAHL

#	Search term(s)
1	(MH 'Birth Order+') OR (MH 'Parity+') OR 'birth order*' OR 'birth rank*' OR 'multiple birth*' OR 'parity'
2	(MH 'Family Characteristics+') OR (MH 'Family Health+') OR 'family charactersitic*' OR 'family size*' OR 'family structure*' OR 'family demograph*' OR 'family composition' OR 'household size*' OR 'household demograph*' OR 'household composition'
3	(MH 'Siblings+') OR (MH 'Sibling Relations+') OR 'sibling*' OR 'sister*' OR 'brother*' OR 'sibship size*' OR 'sibship*'
4	(MH 'Asthma+') OR (MH 'Respiratory Hypersensitivity+') OR 'bronchial asthma*' OR 'exercise-induced asthma' OR 'asthma*' OR 'exercise-induced bronchospasm' OR 'respiratory hypersensitivit*' OR 'airway hyper responsiveness' OR 'airway hyper-responsiveness' OR 'respiratory hyper responsiveness' OR 'respiratory hyper-responsiveness' OR 'wheeze*'
5	(MH 'Hypersensitivity+') OR (MH 'Hypersensitivity, Immediate+') OR (MH 'Hypersensitivity, Delayed+') OR (MH 'Allergy and Immunology+') OR 'immedate hypersensitivit*' OR 'delayed hypersensitivit*' OR 'IgE-mediated hypersensitivit*' OR 'type I hypersensitivit*' OR 'type IV hypersensitivit*' OR 'hypersensitivit*' OR 'atopic sensitization' OR 'atop*' OR 'allergic sensitization' OR 'allergic disease*' OR 'allerg*'

6	(MH 'Dermatitis, Atopic+') OR (MH 'Eczema+') OR (MH 'Angioedema+') OR (MH 'Anaphylaxis+') OR (MH 'Urticaria+') OR 'atopic dermatitis' OR 'dermatitis' OR 'atopic eczema' OR 'eczema' OR 'nerudoarmatiti*' OR "besnier's prurigo" OR 'besniers prurigo' OR 'besnier prurigo' OR 'urticari*' OR 'hives' OR 'anaphyla*' OR "quincke's edema" OR 'quinckes edema' OR 'quincke edema' OR 'angioneurotic edema' OR 'angioedema'
7	(MH 'Food Hypersensitivity+') OR 'food hypersensitivit*' OR 'food allerg*' OR 'egg hypersensitivit*' OR 'egg allerg*' OR 'milk hypersensitivit*' OR 'milk allerg*' OR 'shellfish hypersensitivit*' OR 'shellfish allerg*' OR 'wheat hypersensitivit*' OR 'wheat allerg*' OR 'nut hypersensitivit*' OR 'nut allerg*' OR 'peanut hypersensitivit*' OR 'peanut allerg*' OR 'groundnut hypersensitivit*' OR 'groundnut allerg*'
8	(MH 'Rhinitis, Allergic+') OR (MH 'Rhinitis, Allergic, Seasonal+') OR (MH 'Rhinitis, Allergic, Perennial+') OR (MH 'Rhinitis+') OR (MH 'Conjunctivitis, Allergic+') OR (MH 'Conjunctivitis+') OR 'allergic rhinoconjunctiviti*' OR 'rhinoconjunctiviti*' OR 'allergic rhiniti*' OR 'seasonal allergic rhiniti*' OR 'perennial allergic rhiniti*' OR 'rhiniti*' OR 'allergic conjunctiviti*' OR 'vernal keratoconjunctiviti*' OR 'vernal conjunctiviti*' OR 'giant papillary conjunctiviti*' OR 'hay fever' OR 'hayfever' OR 'pollinosis' OR 'pollenosis' OR 'nasal catarrh'
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
<p>Full query</p> <p>((MH "Birth Order+") OR (MH "Parity+") OR "birth order*" OR "birth rank*" OR "multiple birth*" OR "parity" OR (MH "Family Characteristics+") OR (MH "Family Health+") OR "family charactersitic*" OR "family size*" OR "family structure*" OR "family demograph*" OR "family composition" OR "household size*" OR "household demograph*" OR "household composition" OR (MH "Siblings+") OR (MH "Sibling Relations+") OR "sibling*" OR "sister*" OR "brother*" OR "sibship size*" OR "sibship*") AND ((MH "Asthma+") OR (MH "Respiratory Hypersensitivity+") OR "bronchial asthma*" OR "exercise-induced asthma" OR "asthma*" OR "exercise-induced bronchospasm" OR "respiratory hypersensitivit*" OR "airway hyper responsiveness" OR "airway hyper-responsiveness" OR "respiratory hyper responsiveness" OR "respiratory hyper-responsiveness" OR "wheez*" OR (MH "Hypersensitivity+") OR (MH "Hypersensitivity, Immediate+") OR (MH "Hypersensitivity, Delayed+") OR (MH "Allergy and Immunology+") OR "immedate hypersensitivit*" OR "delayed hypersensitivit*" OR "IgE-mediated hypersensitivit*" OR "type I hypersensitivit*" OR "type IV hypersensitivit*" OR "hypersensitivit*" OR "atopic sensitization" OR "atop*" OR "allergic sensitization" OR "allergic disease*" OR "allerg*" OR (MH "Dermatitis, Atopic+") OR (MH "Eczema+") OR (MH 'Angioedema+') OR (MH 'Anaphylaxis+') OR (MH "Urticaria+") OR "atopic dermatitis" OR "dermatitis" OR "atopic eczema" OR "eczema" OR "nerudoarmatiti*" OR "besnier's prurigo" OR "besniers prurigo" OR "besnier prurigo" OR "urticari*" OR "hives" OR "anaphyla*" OR "quincke's edema" OR "quinckes edema" OR "quincke edema" OR "angioneurotic edema" OR "angioedema" OR (MH "Food Hypersensitivity+") OR "food hypersensitivit*" OR "food allerg*" OR "egg hypersensitivit*" OR "egg allerg*" OR "milk hypersensitivit*" OR "milk allerg*" OR "shellfish hypersensitivit*" OR "shellfish allerg*" OR "wheat hypersensitivit*" OR "wheat allerg*" OR "nut hypersensitivit*" OR "nut allerg*" OR "peanut hypersensitivit*" OR "peanut allerg*" OR "groundnut hypersensitivit*" OR "groundnut allerg*" OR (MH "Rhinitis, Allergic+") OR (MH "Rhinitis, Allergic, Seasonal+") OR (MH "Rhinitis, Allergic, Perennial+") OR (MH "Rhinitis+") OR (MH "Conjunctivitis, Allergic+") OR (MH "Conjunctivitis+") OR "allergic rhinoconjunctiviti*" OR "rhinoconjunctiviti*" OR</p>	

"allergic rhiniti*" OR "seasonal allergic rhiniti*" OR "perennial allergic rhiniti*" OR "rhiniti*" OR "allergic conjunctiviti*" OR "vernal keratoconjunctiviti*" OR "vernal conjunctiviti*" OR "giant papillary conjunctiviti*" OR "hay fever" OR "hayfever" OR "pollinosis" OR "pollenosis" OR "nasal catarrh"))

MH = subject heading

Embase

#	Search term(s)
1	sibship.mp.
2	birth order.mp. or exp birth order/
3	birth rank.mp.
4	multiple birth.mp.
5	parity.mp. or exp parity/
6	family characteristic.mp. or exp family size/
7	family structure.mp.
8	family demograph.mp.
9	family demograph*.mp.
10	family composition.mp.
11	household size.mp.
12	household demograph*.mp.
13	household composition.mp.
14	exp sibling relation/ or sibling.mp. or sibling/
15	exp sister/ or sister.mp.
16	siblings.mp.
17	sisters.mp.
18	brother.mp. or exp brother/
19	brothers.mp.
20	or/1-19
21	exp Asthma/ or (bronchial asthma* or exercise-induced asthma* or exercise-induced bronchospasm* or asthma* or respiratory hypersensitivit* or airway hyper responsiveness or airway hyper-responsiveness or respiratory hyper responsiveness or respiratory hyper-responsiveness or wheez*).mp.
22	exp Hypersensitivity/ or exp Hypersensitivity Immediate/ or exp Hypersensitivity Delayed/ or (immediate hypersensitivit* or delayed hypersensitivit* or IgE-mediated hypersensitivit* or type I hypersensitivit* or type IV hypersensitivit* or atopic sensitization or atop* or allergic sensitization or allerg*).mp.
23	exp Dermatitis/ or exp Anaphylaxis/ or (atopic dermatitis or dermatitis or neurodermatiti* or besnier prurigo or besniers prurigo or besnier prurigo or atopic eczema or eczema or urticari* or anaphyla* or quincke edema or quinckes edema or quincke edema or angioneurotic edema or angioedema or hives).mp.

24	exp Food Hypersensitivity/ or (food hypersensitivit* or food allerg* or egg hypersensitivit* or egg allerg* or milk hypersensitivit* or milk allerg* or shellfish hypersensitivit* or shellfish allerg* or wheat hypersensitivit* or wheat allerg* or nut hypersensitivit* or nut allerg* or peanut hypersensitivit* or peanut allerg* or groundnut hypersensitivit* or groundnut allerg*).mp.
25	exp Rhinitis/ or exp Conjunctivitis/ or (allergic rhinoconjunctiviti* or rhinoconjunctiviti* or allergi rhiniti* or seasonal allergic rhiniti* or perennial allergic rhiniti* or rhiniti* or allergic conjunctiviti* or vernal keratoconjunctiviti* or vernal conjunctiviti* or giant papillary conjunctiviti* or hay fever or hayfever or pollinosis or pollinosis or nasal catarrh*).mp.
26	or/21-25
27	20 and 26

Google Scholar

#	Search term(s)
1	"family size" OR "family structure" OR "household size"
2	"sibling" OR "sibship"
3	"asthma" OR "wheezing"
4	"atopy" OR "allergy"
5	"eczema" OR "urticaria" OR "angioedema" OR "anaphylaxis"
6	"rhinitis" OR "allergic conjunctivitis" OR "hay fever"
7	1 OR 2
8	3 OR 4 OR 5 OR 6
9	7 AND 8
Full query	
("family size" OR "family structure" OR "household size" OR "sibling" OR "sibship") AND ("asthma" OR "wheezing" OR "atopy" OR "allergy" OR "anaphylaxis" OR "eczema" OR "urticaria" OR "angioedema" OR "rhinitis" OR "allergic conjunctivitis" OR "hay fever")	

PsycINFO

#	Search term(s)
1	SU.EXACT.EXPLODE("Birth Order") OR TI,AB("birth order*") OR TI,AB("multiple birth*") OR TI,AB("birth rank*") OR TI,AB("parity")
2	SU.EXACT.EXPLODE("Family Structure") OR SU.EXACT.EXPLODE("Family Size") OR TI,AB("family characteristic*") OR TI,AB("family size*") OR TI,AB("family structure*") OR TI,AB("family demograph*") OR TI,AB("family composition") OR TI,AB("household size*") OR TI,AB("household demograph*") OR TI,AB("household composition")
3	SU.EXACT.EXPLODE("Siblings") OR SU.EXACT.EXPLODE("Sibling Relations") OR TI,AB("sibling*") OR TI,AB("sister*") OR TI,AB("brother*") OR TI,AB("sibship size*") OR TI,AB("sibship size*") OR TI,AB("sibship*")

4	SU.EXACT.EXPLODE("Asthma") OR TI,AB("bronchial asthma*") OR TI,AB("exercise-induced asthma*") OR TI,AB("asthma*") OR TI,AB("exercise-induced bronchospasm*") OR TI,AB("respiratory hypersensitivit*") OR TI,AB("airway hyper responsiveness") OR TI,AB("airway hyper-responsiveness") OR TI,AB("respiratory hyper responsiveness") OR TI,AB("respiratory hyper-responsiveness") OR TI,AB("wheez*")
5	SU.EXACT.EXPLODE("Allergic Disorders") OR TI,AB("immediate hypersensitivit*") OR TI,AB("delayed hypersensitivit*") OR TI,AB("hypersensitivit*") OR TI,AB("IgE-mediated hypersensitivit*") OR TI,AB("type I hypersensitivit*") OR TI,AB("type IV hypersensitivit*") OR TI,AB("atopic sensitization") OR TI,AB("atop*") OR TI,AB("allergic sensitization") OR TI,AB("allergic disease*") OR TI,AB("allerg*")
6	SU.EXACT.EXPLODE("Allergic Skin Disorders") OR SU.EXACT.EXPLODE("Neurodermatitis") OR SU.EXACT.EXPLODE("Dermatitis") OR SU.EXACT.EXPLODE("Eczema") OR SU.EXACT.EXPLODE("Anaphylactic Shock") OR TI,AB("atopic dermatitis") OR TI,AB("dermatitis") OR TI,AB("atopic eczema") OR TI,AB("eczema") OR TI,AB("neurodermatiti*") OR TI,AB("besnier's prurigo") OR TI,AB("besniers prurigo") OR TI,AB("besnier prurigo") OR TI,AB("urticari*") OR TI,AB("hives") OR TI,AB("anaphyla*") OR TI,AB("quincke's edema") OR TI,AB("quinckes edema") OR TI,AB("quincke edema") OR TI,AB("angioneurotic edema") OR TI,AB("angioedema")
7	SU.EXACT.EXPLODE("Food Allergies") OR TI,AB("food hypersensitivit*") OR TI,AB("food allerg*") OR TI,AB("egg hypersensitivit*") OR TI,AB("egg allerg*") OR TI,AB("milk hypersensitivit*") OR TI,AB("milk allerg*") OR TI,AB("shellfish hypersensitivit*") OR TI,AB("shellfish allerg*") OR TI,AB("wheat hypersensitivit*") OR TI,AB("wheat allerg*") OR TI,AB("nut hypersensitivit*") OR TI,AB("nut allerg*") OR TI,AB("peanut hypersensitivit*") OR TI,AB("peanut allerg*") OR TI,AB("groundnut hypersensitivit*") OR TI,AB("groundnut allerg*")
8	TI,AB("allergic rhinoconjunctiviti*") OR TI,AB("rhinoconjunctiviti*") OR TI,AB("allergic rhiniti*") OR TI,AB("rhiniti*") OR TI,AB("seasonal allergic rhiniti*") OR TI,AB("perennial allergic rhiniti*") OR TI,AB("allergic conjunctiviti*") OR TI,AB("vernal keratoconjunctiviti*") OR TI,AB("vernal conjunctiviti*") OR TI,AB("giant papillary conjunctiviti*") OR TI,AB("hay fever") OR TI,AB("hayfever") OR TI,AB("pollinosis") OR TI,AB("pollenosis") OR TI,AB("nasal catarrh*")
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
Full query (SU.EXACT.EXPLODE("Birth Order") OR TI,AB("birth order*") OR TI,AB("multiple birth*") OR TI,AB("birth rank*") OR TI,AB("parity") OR SU.EXACT.EXPLODE("Family Structure") OR SU.EXACT.EXPLODE("Family Size") OR TI,AB("family characteristic*") OR TI,AB("family size*") OR TI,AB("family structure*") OR TI,AB("family demograph*") OR TI,AB("family composition") OR TI,AB("household size*") OR TI,AB("household demograph*") OR TI,AB("household composition") OR SU.EXACT.EXPLODE("Siblings") OR SU.EXACT.EXPLODE("Sibling Relations") OR TI,AB("sibling*") OR TI,AB("sister*") OR TI,AB("brother*") OR	

TI,AB("sibship size*") OR TI,AB("sibship size*") OR TI,AB("sibship*")) AND (SU.EXACT.EXPLODE("Asthma") OR TI,AB("bronchial asthma*") OR TI,AB("exercise-induced asthma*") OR TI,AB("asthma*") OR TI,AB("exercise-induced bronchospasm*") OR TI,AB("respiratory hypersensitivit*") OR TI,AB("airway hyper responsiveness") OR TI,AB("airway hyper-responsiveness") OR TI,AB("respiratory hyper responsiveness") OR TI,AB("respiratory hyper-responsiveness") OR TI,AB("wheez*") OR SU.EXACT.EXPLODE("Allergic Disorders") OR TI,AB("immediate hypersensitivit*") OR TI,AB("delayed hypersensitivit*") OR TI,AB("hypersensitivit*") OR TI,AB("IgE-mediated hypersensitivit*") OR TI,AB("type I hypersensitivit*") OR TI,AB("type IV hypersensitivit") OR TI,AB("atopic sensitization") OR TI,AB("atop*") OR TI,AB("allergic sensitization") OR TI,AB("allergic disease*") OR TI,AB("allerg*") OR SU.EXACT.EXPLODE("Allergic Skin Disorders") OR SU.EXACT.EXPLODE("Neurodermatitis") OR SU.EXACT.EXPLODE("Dermatitis") OR SU.EXACT.EXPLODE("Eczema") OR SU.EXACT.EXPLODE("Anaphylactic Shock") OR TI,AB("atopic dermatitis") OR TI,AB("dermatitis") OR TI,AB("atopic eczema") OR TI,AB("eczema") OR TI,AB("neurodermatiti*") OR TI,AB("besnier's prurigo") OR TI,AB("besniers prurigo") OR TI,AB("besnier prurigo") OR TI,AB("urticari*") OR TI,AB("hives") OR TI,AB("anaphyla*") OR TI,AB("quincke's edema") OR TI,AB("quinckes edema") OR TI,AB("quincke edema") OR TI,AB("angioneurotic edema") OR TI,AB("angioedema") OR SU.EXACT.EXPLODE("Food Allergies") OR TI,AB("food hypersensitivit*") OR TI,AB("food allerg*") OR TI,AB("egg hypersensitivit*") OR TI,AB("egg allerg*") OR TI,AB("milk hypersensitivit*") OR TI,AB("milk allerg*") OR TI,AB("shellfish hypersensitivit*") OR TI,AB("shellfish allerg*") OR TI,AB("wheat hypersensitivit*") OR TI,AB("wheat allerg*") OR TI,AB("nut hypersensitivit*") OR TI,AB("nut allerg*") OR TI,AB("peanut hypersensitivit*") OR TI,AB("peanut allerg*") OR TI,AB("groundnut hypersensitivit*") OR TI,AB("groundnut allerg*") OR TI,AB("allergic rhinoconjunctiviti*") OR TI,AB("rhinoconjunctiviti*") OR TI,AB("allergic rhiniti*") OR TI,AB("rhiniti*") OR TI,AB("seasonal allergic rhiniti*") OR TI,AB("perennial allergic rhiniti*") OR TI,AB("allergic conjunctiviti*") OR TI,AB("vernal keratoconjunctiviti*") OR TI,AB("vernal conjunctiviti*") OR TI,AB("giant papillary conjunctiviti*") OR TI,AB("hay fever") OR TI,AB("hayfever") OR TI,AB("pollinosis") OR TI,AB("pollenosis") OR TI,AB("nasal catarrh*"))

SU = all subjects and indexing; TI,AB = title, abstract

PubMed

#	Search term(s)
1	Birth Order[mh] OR Parity[mh] OR birth order*[tiab] OR multiple birth*[tiab] OR birth rank*[tiab] OR parity[tiab]
2	Family Characteristics[mh] OR Family Health[mh] OR family characteristic*[tiab] OR family size*[tiab] OR family structure*[tiab] OR family demograph*[tiab] OR family composition[tiab] OR household size*[tiab] OR household demograph*[tiab] OR household composition[tiab]
3	Siblings[mh] OR Sibling Relations[mh] OR sibling*[tiab] OR sister*[tiab] OR brother*[tiab] OR sibship size*[tiab] OR sibship*[tiab]
4	Asthma[mh] OR Asthma, Exercise-Induced[mh] OR Respiratory Hypersensitivity[mh] OR bronchial asthma*[tiab] OR exercise-induced asthma*[tiab] OR exercise-induced bronchospasm*[tiab] OR asthma*[tiab] OR respiratory hypersensitivit*[tiab] OR airway hyper responsiveness[tiab] OR airway hyper-responsiveness[tiab] OR respiratory hyper responsiveness[tiab] OR respiratory hyper-responsiveness[tiab] OR wheez*[tiab]

5	Hypersensitivity[mh] OR Hypersensitivity, Immediate[mh] OR Hypersensitivity, Delayed[mh] OR Allergy and Immunology[mh] OR Allergens / Immunology[mh] OR immediate hypersensitivit*[tiab] OR delayed hypersensitivit*[tiab] OR hypersensitivit*[tiab] OR IgE-mediated hypersensitivit*[tiab] OR type I hypersensitivit*[tiab] OR type IV hypersensitivit*[tiab] OR atopic sensitization[tiab] OR atop*[tiab] OR allergic sensitization[tiab] OR allergic disease*[tiab] OR allerg*[tiab]
6	Dermatitis, Atopic[mh] OR Eczema[mh] OR Angioedema[mh] OR Anaphylaxis[mh] OR Urticaria[mh] OR atopic dermatitis[tiab] OR dermatitis[tiab] OR atopic eczema[tiab] OR eczema[tiab] OR neurodermatiti*[tiab] OR besnier's prurigo[tiab] OR besniers prurigo[tiab] OR besnier prurigo[tiab] OR urticari*[tiab] OR anaphyla*[tiab] OR quincke edema[tiab] OR quinckes edema[tiab] OR quincke's edema[tiab] OR angioneurotic edema[tiab] OR angioedema[tiab] OR hives[tiab]
7	Food Hypersensitivity[mh] OR food hypersensitivit*[tiab] OR food allerg*[tiab] OR egg allerg*[tiab] OR egg hypersensitivit*[tiab] OR milk allerg*[tiab] OR milk hypersensitivit*[tiab] OR shellfish allerg*[tiab] OR shellfish hypersensitivit*[tiab] OR wheat allerg*[tiab] OR wheat hypersensitivit*[tiab] OR nut allerg*[tiab] OR nut hypersensitivit*[tiab] OR peanut allerg*[tiab] OR peanut hypersensitivit*[tiab] OR groundnut hypersensitivit*[tiab]
8	Pollen / Immunology[mh] OR Rhinitis, Allergic[mh] OR Rhinitis, Allergic, Seasonal[mh] OR Rhinitis, Allergic, Perennial[mh] OR Rhinitis[mh] OR Conjunctivitis, Allergic[mh] OR Conjunctivitis / Immunology[mh] OR Conjunctivitis / Epidemiology[mh] OR Conjunctivitis / Etiology[mh] OR allergic rhinoconjunctiviti*[tiab] OR rhinoconjunctiviti*[tiab] OR allergic rhiniti*[tiab] OR rhiniti*[tiab] OR seasonal allergic rhiniti*[tiab] OR perennial allergic rhiniti*[tiab] OR allergic conjunctiviti*[tiab] OR vernal keratoconjunctiviti*[tiab] OR vernal conjunctiviti*[tiab] OR giant papillary conjunctiviti*[tiab] OR hay fever[tiab] OR hayfever[tiab] OR pollinosis[tiab] OR pollenosis[tiab] OR nasal catarrh*[tiab]
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
<p>Full query</p> <p>(Birth Order[mh] OR Parity[mh] OR birth order*[tiab] OR multiple birth*[tiab] OR birth rank*[tiab] OR parity[tiab] OR Family Characteristics[mh] OR Family Health[mh] OR family characteristic*[tiab] OR family size*[tiab] OR family structure*[tiab] OR family demograph*[tiab] OR family composition[tiab] OR household size*[tiab] OR household demograph*[tiab] OR household composition[tiab] OR Siblings[mh] OR Sibling Relations[mh] OR sibling*[tiab] OR sister*[tiab] OR brother*[tiab] OR sibship size*[tiab] OR sibship*[tiab]) AND (Asthma[mh] OR Asthma, Exercise-Induced[mh] OR Respiratory Hypersensitivity[mh] OR bronchial asthma*[tiab] OR exercise-induced asthma*[tiab] OR exercise-induced bronchospasm*[tiab] OR asthma*[tiab] OR respiratory hypersensitivit*[tiab] OR airway hyper responsiveness[tiab] OR airway hyper-responsiveness[tiab] OR respiratory hyper responsiveness[tiab] OR respiratory hyper-responsiveness[tiab] OR wheez*[tiab] OR Hypersensitivity[mh] OR Hypersensitivity, Immediate[mh] OR Hypersensitivity, Delayed[mh] OR Allergy and Immunology[mh] OR Allergens / Immunology[mh] OR immediate hypersensitivit*[tiab] OR delayed hypersensitivit*[tiab] OR hypersensitivit*[tiab] OR IgE-mediated hypersensitivit*[tiab] OR type I hypersensitivit*[tiab] OR type IV hypersensitivit*[tiab] OR atopic sensitization[tiab] OR atop*[tiab] OR allergic sensitization[tiab] OR allergic disease*[tiab] OR allerg*[tiab] OR Dermatitis, Atopic[mh] OR Eczema[mh] OR Angioedema[mh] OR Anaphylaxis[mh] OR Urticaria[mh] OR atopic dermatitis[tiab] OR dermatitis[tiab] OR atopic eczema[tiab] OR eczema[tiab] OR neurodermatiti*[tiab] OR besnier's prurigo[tiab] OR besniers prurigo[tiab] OR besnier prurigo[tiab] OR urticari*[tiab] OR anaphyla*[tiab] OR quincke edema[tiab] OR quinckes edema[tiab] OR quincke's edema[tiab] OR angioneurotic edema[tiab] OR angioedema[tiab] OR hives[tiab])</p>	

OR Food Hypersensitivity[mh] OR food hypersensitiv*[tiab] OR food allerg*[tiab] OR egg allerg*[tiab] OR egg hypersensitiv*[tiab] OR milk allerg*[tiab] OR milk hypersensitiv*[tiab] OR shellfish allerg*[tiab] OR shellfish hypersensitiv*[tiab] OR wheat allerg*[tiab] OR wheat hypersensitiv*[tiab] OR nut allerg*[tiab] OR nut hypersensitiv*[tiab] OR peanut allerg*[tiab] OR peanut hypersensitiv*[tiab] OR groundnut hypersensitiv*[tiab] OR Pollen / Immunology[mh] OR Rhinitis, Allergic[mh] OR Rhinitis, Allergic, Seasonal[mh] OR Rhinitis, Allergic, Perennial[mh] OR Rhinitis[mh] OR Conjunctivitis, Allergic[mh] OR Conjunctivitis / Immunology[mh] OR Conjunctivitis / Epidemiology[mh] OR Conjunctivitis / Etiology[mh] OR allergic rhinoconjunctiviti*[tiab] OR rhinoconjunctiviti*[tiab] OR allergic rhiniti*[tiab] OR rhiniti*[tiab] OR seasonal allergic rhiniti*[tiab] OR perennial allergic rhiniti*[tiab] OR allergic conjunctiviti*[tiab] OR vernal keratoconjunctivitis*[tiab] OR vernal conjunctiviti*[tiab] OR giant papillary conjunctiviti*[tiab] OR hay fever[tiab] OR hayfever[tiab] OR pollinosis[tiab] OR pollinosis[tiab] OR nasal catarrh*[tiab])

mh = MeSH; tiab = title, abstract

Scopus

#	Search term(s)
1	TITLE-ABS-KEY("birth order*") OR TITLE-ABS-KEY("multiple birth*") OR TITLE-ABS-KEY("birth rank*") OR TITLE-ABS-KEY("parity")
2	TITLE-ABS-KEY("family characteristic*") OR TITLE-ABS-KEY("family size*") OR TITLE-ABS-KEY("family structure*") OR TITLE-ABS-KEY("family demograph*") OR TITLE-ABS-KEY("family composition") OR TITLE-ABS-KEY("household size*") OR TITLE-ABS-KEY("household demograph*") OR TITLE-ABS-KEY("household composition*")
3	TITLE-ABS-KEY("sibling relation*") OR TITLE-ABS-KEY("sibling*") OR TITLE-ABS-KEY("brother*") OR TITLE-ABS-KEY("sister*") OR TITLE-ABS-KEY("sibship size*") OR TITLE-ABS-KEY("sibship*")
4	TITLE-ABS-KEY("bronchial asthma*") OR TITLE-ABS-KEY("exercise-induced asthma*") OR TITLE-ABS-KEY("asthma*") OR TITLE-ABS-KEY("exercise-induced bronchospasm*") OR TITLE-ABS-KEY("respiratory hypersensitiv*") OR TITLE-ABS-KEY("airway hyper responsiveness") OR TITLE-ABS-KEY("airway hyper-responsiveness") OR TITLE-ABS-KEY("respiratory hyper responsiveness") OR TITLE-ABS-KEY("respiratory hyper-responsiveness") OR TITLE-ABS-KEY("wheez*")
5	TITLE-ABS-KEY("immediate hypersensitiv*") OR TITLE-ABS-KEY("delayed hypersensitiv*") OR TITLE-ABS-KEY("IgE-mediated hypersensitiv*") OR TITLE-ABS-KEY("type I hypersensitiv*") OR TITLE-ABS-KEY("type IV hypersensitiv*") OR TITLE-ABS-KEY("atopic sensitization") OR TITLE-ABS-KEY("atop*") OR TITLE-ABS-KEY("allergic sensitization") OR TITLE-ABS-KEY("allergic disease") OR TITLE-ABS-KEY("allerg*")
6	TITLE-ABS-KEY("atopic dermatitis") OR TITLE-ABS-KEY("dermatitis") OR TITLE-ABS-KEY("atopic eczema") OR TITLE-ABS-KEY("eczema") OR TITLE-ABS-KEY("neurodermatitis*") OR TITLE-ABS-KEY("besnier's prurigo") OR TITLE-ABS-KEY("besniers prurigo") OR TITLE-ABS-KEY("besnier prurigo") OR TITLE-ABS-KEY("quincke's edema") OR TITLE-ABS-KEY("quinckes edema") OR TITLE-ABS-KEY("quincke edema") OR TITLE-ABS-KEY("angioneurotic edema") OR TITLE-ABS-KEY("hives") OR TITLE-ABS-KEY("anaphyla*") OR TITLE-ABS-KEY("urticari*")

7	TITLE-ABS-KEY("food hypersensitivit*") OR TITLE-ABS-KEY("food allerg*") OR TITLE-ABS-KEY("egg allerg*") OR TITLE-ABS-KEY("egg hypersensitivit*") OR TITLE-ABS-KEY("milk allerg*") OR TITLE-ABS-KEY("milk hypersensitivit*") OR TITLE-ABS-KEY("shellfish allerg*") OR TITLE-ABS-KEY("shellfish hypersensitivit*") OR TITLE-ABS-KEY("wheat allerg*") OR TITLE-ABS-KEY("wheat hypersensitivit*") OR TITLE-ABS-KEY("nut allerg*") OR TITLE-ABS-KEY("nut hypersensitivit*") OR TITLE-ABS-KEY("peanut allerg*") OR TITLE-ABS-KEY("peanut hypersensitivit*") OR TITLE-ABS-KEY("groundnut allerg*") OR TITLE-ABS-KEY("groundnut hypersensitivit*")
8	TITLE-ABS-KEY("allergic rhinoconjunctiviti*") OR TITLE-ABS-KEY("rhinoconjunctiviti*") OR TITLE-ABS-KEY("seasonal allergic rhiniti*") OR TITLE-ABS-KEY("perennial allergic rhiniti*") OR TITLE-ABS-KEY("allergic rhiniti*") OR TITLE-ABS-KEY("rhiniti*") OR TITLE-ABS-KEY("allergic conjunctiviti*") OR TITLE-ABS-KEY("vernal keratoconjunctiviti*") OR TITLE-ABS-KEY("vernal conjunctiviti*") OR TITLE-ABS-KEY("giant papillary conjunctiviti*") OR TITLE-ABS-KEY("hay fever") OR TITLE-ABS-KEY("hayfever") OR TITLE-ABS-KEY("pollinosis") OR TITLE-ABS-KEY("pollenosis") OR TITLE-ABS-KEY("nasal catarrh*")
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
<p>Full query</p> <p>(TITLE-ABS-KEY("birth order*") OR TITLE-ABS-KEY("multiple birth*") OR TITLE-ABS-KEY("birth rank*") OR TITLE-ABS-KEY("parity") OR TITLE-ABS-KEY("family characteristic*") OR TITLE-ABS-KEY("family size*") OR TITLE-ABS-KEY("family structure*") OR TITLE-ABS-KEY("family demograph*") OR TITLE-ABS-KEY("family composition") OR TITLE-ABS-KEY("household size*") OR TITLE-ABS-KEY("household demograph*") OR TITLE-ABS-KEY("household composition*") OR TITLE-ABS-KEY("sibling relation*") OR TITLE-ABS-KEY("sibling*") OR TITLE-ABS-KEY("brother*") OR TITLE-ABS-KEY("sister*") OR TITLE-ABS-KEY("sibship size*") OR TITLE-ABS-KEY("sibship*")) AND (TITLE-ABS-KEY("bronchial asthma*") OR TITLE-ABS-KEY("exercise-induced asthma*") OR TITLE-ABS-KEY("asthma*") OR TITLE-ABS-KEY("exercise-induced bronchospasm*") OR TITLE-ABS-KEY("respiratory hypersensitivit*") OR TITLE-ABS-KEY("airway hyper responsiveness") OR TITLE-ABS-KEY("airway hyper-responsiveness") OR TITLE-ABS-KEY("respiratory hyper responsiveness") OR TITLE-ABS-KEY("respiratory hyper-responsiveness") OR TITLE-ABS-KEY("wheez*") OR TITLE-ABS-KEY("immediate hypersensitivit*") OR TITLE-ABS-KEY("delayed hypersensitivit*") OR TITLE-ABS-KEY("IgE-mediated hypersensitivit*") OR TITLE-ABS-KEY("type I hypersensitivit*") OR TITLE-ABS-KEY("type IV hypersensitivit*") OR TITLE-ABS-KEY("atopic sensitization") OR TITLE-ABS-KEY("atop*") OR TITLE-ABS-KEY("allergic sensitization") OR TITLE-ABS-KEY("allergic disease") OR TITLE-ABS-KEY("allerg*") OR TITLE-ABS-KEY("atopic dermatitis") OR TITLE-ABS-KEY("dermatitis") OR TITLE-ABS-KEY("atopic eczema") OR TITLE-ABS-KEY("eczema") OR TITLE-ABS-KEY("neurodermatitis*") OR TITLE-ABS-KEY("besnier's prurigo") OR TITLE-ABS-KEY("besniers prurigo") OR TITLE-ABS-KEY("besnier prurigo") OR TITLE-ABS-KEY("quincke's edema") OR TITLE-ABS-KEY("quinckes edema") OR TITLE-ABS-KEY("quincke edema") OR TITLE-ABS-KEY("angioneurotic edema") OR TITLE-ABS-KEY("hives") OR TITLE-ABS-KEY("anaphyla*") OR TITLE-ABS-KEY("urticari*") OR TITLE-ABS-KEY("food hypersensitivit*") OR TITLE-ABS-KEY("food allerg*") OR TITLE-ABS-KEY("egg allerg*") OR TITLE-ABS-KEY("egg hypersensitivit*") OR TITLE-ABS-KEY("milk allerg*") OR TITLE-ABS-KEY("milk hypersensitivit*") OR TITLE-ABS-KEY("shellfish allerg*") OR TITLE-ABS-KEY("shellfish</p>	

hypersensitivit*") OR TITLE-ABS-KEY("wheat allerg*") OR TITLE-ABS-KEY("wheat hypersensitivit*") OR TITLE-ABS-KEY("nut allerg*") OR TITLE-ABS-KEY("nut hypersensitivit*") OR TITLE-ABS-KEY("peanut allerg*") OR TITLE-ABS-KEY("peanut hypersensitivit*") OR TITLE-ABS-KEY("groundnut allerg*") OR TITLE-ABS-KEY("groundnut hypersensitivit*") OR TITLE-ABS-KEY("allergic rhinoconjunctiviti*") OR TITLE-ABS-KEY("rhinoconjunctiviti*") OR TITLE-ABS-KEY("seasonal allergic rhiniti*") OR TITLE-ABS-KEY("perennial allergic rhiniti*") OR TITLE-ABS-KEY("allergic rhiniti*") OR TITLE-ABS-KEY("rhiniti*") OR TITLE-ABS-KEY("allergic conjunctiviti*") OR TITLE-ABS-KEY("vernal keratoconjunctiviti*") OR TITLE-ABS-KEY("vernal conjunctiviti*") OR TITLE-ABS-KEY("giant papillary conjunctiviti*") OR TITLE-ABS-KEY("hay fever") OR TITLE-ABS-KEY("hayfever") OR TITLE-ABS-KEY("pollinosis") OR TITLE-ABS-KEY("pollenosis") OR TITLE-ABS-KEY("nasal catarrh*"))

TITLE-ABS-KEY = title, abstract, keywords

Web of Science

#	Search term(s)
1	TS="birth order*" OR TS="multiple birth*" OR TS="birth rank*" OR TS="parity"
2	TS="family characteristic*" OR TS="family size*" OR TS="family structure*" OR TS="family demograph*" OR TS="family composition" OR TS="household size*" OR TS="household demograph*" OR TS="household composition"
3	TS="sibling*" OR TS="sister*" OR TS="brother*" OR TS="sibship size*" OR TS="sibship"
4	TS="bronchial asthma*" OR TS="exercise-induced asthma*" OR TS="exercise-induced bronchospasm*" OR TS="asthma*" OR TS="respiratory hypersensitivit*" OR TS="respiratory hyper-responsiveness*" OR TS="airway hyper responsiveness*" OR TS="airway hyper-responsiveness*" OR TS=wheez*
5	TS="immediate hypersensitivit*" OR TS="delayed hypersensitivit*" OR TS="IgE-mediated hypersensitivit*" OR TS="type I hypersensitivit*" OR TS="type IV hypersensitivit*" OR TS="hypersensitivit*" OR TS="atopic sensitization" OR TS="atop*" OR TS="allergic sensitization" OR TS="allergic disease*" OR TS="allerg*"
6	TS="atopic dermatitis" OR TS="dermatitis" OR TS="atopic eczema" OR TS="eczema" OR TS="neurodermatiti*" OR TS="besnier's prurigo" OR TS="besniers prurigo" OR TS="besnier prurigo" OR TS="urticari*" OR TS="anaphyla*" OR TS="quincke's edema" OR TS="quinckes edema" OR TS="quincke edema" OR TS="angioneurotic edema" OR TS="angioedema" OR TS="hives"
7	TS="food hypersensitivit*" OR TS="food allerg*" OR TS="egg allerg*" OR TS="egg hypersensitivit*" OR TS="milk allerg*" OR TS="milk hypersensitivit*" OR TS="shellfish allerg*" OR TS="shellfish hypersensitivit*" OR TS="wheat allerg*" OR TS="wheat hypersensitivit*" OR TS="nut allerg*" OR TS="nut hypersensitivit*" OR TS="peanut allerg*" OR TS="peanut hypersensitivit*" OR TS="groundnut allerg*" OR TS="groundnut hypersensitivit*"
8	TS="pollen allerg*" OR TS="allergic rhinoconjunctiviti*" OR TS="rhinoconjunctiviti*" OR TS="seasonal allergic rhiniti*" OR TS="perennial allergic rhiniti*" OR TS="allergic rhiniti*" OR TS="rhiniti*" OR TS="allergic conjunctiviti*" OR TS="vernal keratoconjunctiviti*" OR

	TS="vernal conjunctiviti*" OR TS="giant papillary conjunctiviti*" OR TS="hay fever" OR TS="hayfever" OR TS="pollinosis" OR TS="pollenosis" OR TS="nasal catarrh*"
9	1 OR 2 OR 3
10	4 OR 5 OR 6 OR 7 OR 8
11	9 AND 10
<p>Full query</p> <p>(TS="birth order*" OR TS="multiple birth*" OR TS="birth rank*" OR TS="parity" OR TS="family characteristic*" OR TS="family size*" OR TS="family structure*" OR TS="family demograph*" OR TS="family composition" OR TS="household size*" OR TS="household demograph*" OR TS="household composition" OR TS="sibling*" OR TS="sister*" OR TS="brother*" OR TS="sibship size*" OR TS="sibship*") AND (TS="bronchial asthma*" OR TS="exercise-induced asthma*" OR TS="exercise-induced bronchospasm*" OR TS="asthma*" OR TS="respiratory hypersensitivit*" OR TS="respiratory hyper-responsiveness*" OR TS="airway hyper responsiveness*" OR TS="airway hyper-responsiveness*" OR TS="wheeze*" OR TS="immediate hypersensitivit*" OR TS="delayed hypersensitivit*" OR TS="IgE-mediated hypersensitivit*" OR TS="type I hypersensitivit*" OR TS="type IV hypersensitivit*" OR TS="hypersensitivit*" OR TS="atopic sensitization" OR TS="atop*" OR TS="allergic sensitization" OR TS="allergic disease*" OR TS="allerg*" OR TS="atopic dermatitis" OR TS="dermatitis" OR TS="atopic eczema" OR TS="eczema" OR TS="neurodermatiti*" OR TS="besnier's prurigo" OR TS="besniers prurigo" OR TS="besnier prurigo" OR TS="urticari*" OR TS="anaphyla*" OR TS="quincke's edema" OR TS="quinckes edema" OR TS="quincke edema" OR TS="angioneurotic edema" OR TS="angioedema" OR TS="hives" OR TS="food hypersensitivit*" OR TS="food allerg*" OR TS="egg allerg*" OR TS="egg hypersensitivit*" OR TS="milk allerg*" OR TS="milk hypersensitivit*" OR TS="shellfish allerg*" OR TS="shellfish hypersensitivit*" OR TS="wheat allerg*" OR TS="wheat hypersensitivit*" OR TS="nut allerg*" OR TS="nut hypersensitivit*" OR TS="peanut allerg*" OR TS="peanut hypersensitivit*" OR TS="groundnut allerg*" OR TS="groundnut hypersensitivit*" OR TS="pollen allerg*" OR TS="allergic rhinoconjunctiviti*" OR TS="rhinoconjunctiviti*" OR TS="seasonal allergic rhiniti*" OR TS="perennial allergic rhiniti*" OR TS="allergic rhiniti*" OR TS="rhiniti*" OR TS="allergic conjunctiviti*" OR TS="vernal keratoconjunctiviti*" OR TS="vernal conjunctiviti*" OR TS="giant papillary conjunctiviti*" OR TS="hay fever" OR TS="hayfever" OR TS="pollinosis" OR TS="pollenosis" OR TS="nasal catarrh*")</p>	

TS = title, abstract, author keywords, Keywords Plus

Appendix to

Sibship Size, Birth Order and Risk of Asthma and Allergy: Protocol for a Systematic Review and Meta-Analysis

Daniil Lisik, Athina Ioannidou, Gregorio Paolo Milani, Sungkutu Nyassi, Saliha Selin Özüygür Ermis, Giulia Spolidoro, Emma Goksör, Göran Wennergren, Bright I Nwaru

Appendix 3: Data Extraction Form

Reviewer (initials)	
Date of data extraction (yyyy-mm-dd)	
General information	
Author (for first author: surname, given name(s))	
Title of article	
Year of publication	
Country of origin of study	
Contact information to author(s)	
Study characteristics	
Study design	
Study aims/objectives	
Exposure(s) (for each exposure: 1) method(s) of assessment; 2) objectivity of assessment (objective/subjective ¹); 3) validity (yes ² /no); 4) reliability (yes ³ /no)	
Outcome(s) (for each outcome: 1) method(s) of assessment; 2) objectivity (objective/subjective ⁴); 3) validity (yes ² /no); 4) reliability (yes ³ /no)	
Follow-up (method; length)	Method: Length: Or: <input type="checkbox"/> not applicable
Study was conducted during (year(s))	
Participant selection	
Inclusion criteria	
Exclusion criteria	
Source(s) of subjects	
Population characteristics	
Participants recruited (n; details)	n: Details:

Participants eligible (n; % of “Participants recruited”; eligibility criteria)	n: % of “Participants recruited”: Eligibility criteria:
Participants included (n; % of “Participants eligible”)	n: % of “Participants eligible”: Or:
Participants completing follow-up (n; % of “Participants included”)	n: % of “Participants included”: Or:
Participants lost (n; % of “Participants included”; details; how it was dealt with)	n: % of “Participants included”: Details: How it was dealt with: Or:
Data lost (n; % of “Participants included”; details; how it was dealt with)	n: % of “Participants included”: Details: How it was dealt with:
Participants characteristics (for each group: 1) n_{total} ; 2) age (mean (SD)); 3) gender distribution (n_{males} (% of n_{total})); 4) ethnicity; 5) country; 6) economic classification of country by the World Bank; 7) setting; 8) co-morbidity)	
Results	
Outcomes (for each outcome for each exposure, stratified by group ⁵ if applicable: 1) n (% of n_{group}); 2) effect size (measure of effect) 95% CI; 3) p-value)	
Analysis	
Statistical analysis method	
Confounders (what confounders were identified; how they were controlled for; % of confounders controlled for)	Confounders identified: How they were controlled for: % of confounders controlled for:
Free-text interpretation of findings/conclusion	
Generalizability (is it likely that individuals selected for this study to be representative of the target population?)	
Miscellaneous	
Other comments/notes	

Quality assessment (based on the Effective Public Health Practice Project (EPHPP) quality assessment tool⁶)	
(A) Selection bias	
(Q1) Is it likely that individuals selected for this study to be representative of the target population?	
(Q2) How many of eligible individuals agreed to participate in the study? (%)	
Section rating	
(B) Study design	
Indicate the design of the study	
Was the study setting randomized? If “No”, go to (C)	
If “Yes”, was the randomization method described?	
If “Yes”, was the method referred to above appropriate?	
Section rating Rate longitudinal studies as “moderate”, and cross-sectional studies as “weak”	
(C) Confounders	
(Q1) Did the groups have significant differences in relation to each other prior to the intervention?	
(Q2) If “Yes”, indicate how many relevant confounders that were controlled for in any way (e.g. in study design through matching, stratification, or in analysis) (%)	
Section rating Rate studies without a control group as weak	
(D) Blinding	
(Q1) Did the outcome assessor(s) know about the exposure status of the participants?	
(Q2) Did the participants of the study know about the research question?	
Section rating Rate as “weak” if Q1 is 1 and Q2 is 3	
(E) Data collection methods	
(Q1) Were the tools used for data collection shown to be valid?	
(Q2) Were the tools used for data collection shown to be reliable?	

Section rating	
(F) Withdrawals and drop-outs	
(Q1) Did numbers and/or reasons for withdrawals and drop-outs per group get documented?	
(Q2) How many participants completed the study (if the value is different between groups, state the lowest)? (%)	
Section rating	
Global rating	
Did the two reviewers give different section ratings for A-F?	
If “Yes”, what is the reason for the difference(s)?	
Final rating of both reviewers	

¹ Objective: medical records/official statistics. Subjective: self-report, observation.

² Yes: The assessment gives usable, meaningful information for the research question.

³ Yes: Results from assessment type are consistent and stable.

⁴ Objective: ICD code, verified diagnosis based on medical examination. Subjective: otherwise observed or self-reported symptoms/disease.

⁵ Applicable if specific stratification has been made in the analysis, e.g. significant differences and/or calculations based on gender of participants.

⁶ Modified version of EPHPP [1]. Original tool is available at: <https://www.ehpp.ca/quality-assessment-tool-for-quantitative-studies/>. The questions and answer alternatives are modified in phrasing for readability and the nature of relevant studies. Modifications of rating are clarified in green text above, based on the modifications of EPHPP done in a systematic review by Smith et al. in 2017 [2].

References

1. Armijo-Olivo S, Stiles CR, Hagen NA, Biondo PD, Cummings GG. Assessment of study quality for systematic reviews: a comparison of the Cochrane Collaboration Risk of Bias Tool and the Effective Public Health Practice Project Quality Assessment Tool: methodological research. *J Eval Clin Pract*. 2012;18(1):12-18.
2. Smith M, Hosking J, Woodward A, Witten K, MacMillan A, Field A, et al. Systematic literature review of built environment effects on physical activity and active transport – an update and new findings on health equity. *International Journal of Behavioral Nutrition and Physical Activity*. 2017;14(1):158.